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Abstract 
 
Androgen signaling through the androgen receptor (AR) is essential for normal 
growth and function of the prostate gland. In prostate cancer (PC), androgens provide the 
main proliferative drive for the disease, making androgen-deprivation one of the primary 
therapeutic strategies. Although initially effective, such treatments select for tumor cells 
that are able to sustain proliferation in a reduced androgen environment.  This allows for 
the emergence of castration resistant PC, an incurable disease where both the AR 
transcriptional program is subverted and cellular senescence is evaded. SUMOylation is a 
post-translational modification that regulates both of these processes. SUMOylation of AR 
inhibits both basal and androgen-stimulated transcription in a promoter context manner and 
enhanced global SUMO modification induces prostate cell senescence.  Advanced PC cells 
evade these mechanisms at least in part through the upregulation of SENP1, a SUMO-
specific cysteine protease that reverses SUMOylation. In addition, AR is a direct activator 
of the SENP1 gene, creating a self-reinforcing loop that promotes and sustains its own 
activity and PC progression. 
This dissertation is aimed at the discovery and development of small molecule 
inhibitors of SENP1 as the basis for novel prostate cancer therapeutics. Using a robust 
FRET-based assay, we defined the kinetic properties of SENP1 and its closest paralog 
SENP2. This analysis revealed significant product inhibition and a differential sensitivity 
to ionic strength. Using this assay, an extensive high-throughput screening campaign led 
to the identification of two structurally distinct inhibitor classes. Characterization of these 
 xi 
compounds indicates that they display significant selectivity towards SENP1 relative to 
SENP2 and that they act in both a reversible and competitive manner. Furthermore, these 
compounds inhibit native full-length SENP1 acting on endogenous SUMOylated 
substrates. Notably, both groups of compounds are known to display activity as purinergic 
receptor antagonists. The remarkable parallel pharmacology to P2X1 receptors led to our 
discovery that ATP, the endogenous P2X ligand, is a SENP1 selective inhibitor. We have 
thus revealed a novel nucleotide mediated regulation of SENP1. Using a combination of 
mutagenesis, biochemical assays, and fluorescence and NMR spectroscopy, we have 
characterized the binding of inhibitors and identified key enzyme residues involved in the 
interactions as well as residues responsible for SENP isoform selectivity.   
These findings reveal that SENP1 harbors a unique binding site for nucleotides that 
can be targeted by small molecules. This knowledge can guide novel strategies for further 
inhibitor development for evaluation of the therapeutic efficacy of SENP1 inhibitors in 
advanced prostate cancer models.
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Chapter 1  
 
Introduction to post-translational modification by SUMO and its roles 
in the modulation of function and disease 
1. Overview 
 
Despite containing the same copy of DNA, the types of cells in the human body 
vary widely and execute an even wider array of functions to maintain the homeostasis of 
our complex biology.  The breadth of cell type and function is the product of a variety of 
mechanisms that maintain exquisite control over the transcription, translation, degradation, 
and post-translational modifications of protein products.  Transcription, the process of 
generating messenger RNA (mRNA) from parent DNA, and translation, the process of 
chemically translating mRNA to generate protein, are two of the most fundamental 
activities of cells.  Proteins execute many of the structural, enzymatic, and messenger 
responsibilities of the cell.  In opposition to transcription and translation for protein 
synthesis is protein degradation.  To achieve cellular homeostasis, competition between 
synthesis and degradation allow cells to balance the levels and types of proteins available 
in accordance with the needs of the cell.  These competing processes are nonetheless 
essential and vary in response to stimuli.  However, their rate of response is not always 
rapid enough for meeting all cellular needs.   
Post-translational modification of proteins adds another layer of control to protein 
function.  The plasticity of these modifications allows for dynamic control of protein 
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function that can be more rapid than the transcription/translation and degradation options.  
In turn, transcription and translation themselves can be regulated by post-translational 
modification of the proteins involved in these processes.  There are over 400 unique post-
translational modifications (PTMs) that are grouped into 25 identified major categories 
(Khoury et al., 2011). These PTMs include small chemical groups (such as phosphate, 
hydroxyl, methyl, and acetyl groups), various lipids, arrays of sugars with many different 
branching types, and other proteins.  Of the 20 natural amino acids, 15 have been observed 
to be post-translationally modified (Walsh et al., 2005).  Altogether, these PTMs can result 
in a change in the localization, activity, stability, and/or the interactome of the modified 
protein.  Working as an on-off switch or operating within a continuum, most of these PTMs 
are reversible.  This can allow for dramatic and prompt changes in the function of a protein 
between the two or more states with cell-altering consequences.  Due to their significant 
role in cellular homeostasis and the disease consequences when they go awry, PTMs are 
of significant interest in biomedical research. 
2. Ubiquitin 
 
Among the many types of PTMs and compared to phosphorylation, the discovery 
and research on protein-based PTMs is still young with many unknowns despite their 
central role in regulating cell biology functions.  Discovered in 1975, the appropriately 
named ubiquitin is a protein-based PTM that has been found to be conjugated to tens of 
thousands of proteins (Cappadocia and Lima, 2017; Chen et al., 2014; Schlesinger et al., 
1975).  With only three conservative mutations from yeast to human, ubiquitin is one of 
the most invariant proteins across species (Komander and Rape, 2012).  Ubiquitin is a small 
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8.5 kDa protein that modifies other proteins commonly through conjugation of its C-
terminal glycine residue to the epsilon-amino group (e-NH3+) of a lysine on the target 
protein, creating an isopeptide bond.  This conjugation is executed through a pathway 
involving a series of enzymes known as E1, E2, and E3 enzymes (Hershko et al., 1983).  
E1 enzymes are known as the activating enzymes, where the enzyme activates ubiquitin 
through an ATP and magnesium-dependent process.  Through the action of E1 activating 
enzymes, ubiquitin is first adenylated yielding AMP at its C-terminus and pyrophosphate.  
The E1 catalytic cysteine then attacks the C-terminal carbonyl carbon of the adenylated 
ubiquitin to release AMP and form a thioester intermediate linking E1 and ubiquitin.  
Lastly, the E1 activating enzymes catalyze the trans-thioesterification of ubiquitin to E2 
enzymes.  The E2 enzymes, known as the conjugating enzymes, carry the charged ubiquitin 
and coordinate with an E3 enzyme and a target protein substrate.  E2 conjugating enzymes 
can also directly catalyze the transfer of ubiquitin to target substrate in the absence of an 
E3 enzyme.  The E3 family of ligases contains nearly 600 members and are divided into 
three recognized classes based on their domains: really interesting new gene (RING), 
homologous to the E6-AP carboxyl terminus (HECT), and RING in between RING (RBR) 
(Chymkowitch et al., 2011; Kodadek et al., 2006).  The RING class of E3 ligases is the 
largest and act as scaffolds in coordinating the ubiquitin-linked E2 enzyme and the target 
substrate for E2-catalyzed transfer.  In contrast, the HECT and RBR classes operate under 
a two-step process where the ubiquitin is passed from the E2 to a catalytic cysteine on the 
E3, followed by transfer to the target substrate lysine.  In the ubiquitin pathway, there are 
two E1s, around 45 E2s, and over a thousand E3s encoded in the human genome that 
together help ubiquitinate a multitude of protein targets (Jin et al., 2007; Wenzel et al., 
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2011; Zhao et al., 2012).  The complexity and number of permutations involved in 
understanding the specificity of linkage between target proteins to the array enzymes in 
E1, E2, E3 pathways remains limited.   
Embedded in the complexity of ubiquitination pathways and associated targets are 
the wide range of functional consequences of this modification.  In addition to 
ubiquitination occurring on different unique proteins and on multiple potential sites within 
some proteins, perhaps ubiquitin’s most notable conjugation pattern is ubiquitin-modified 
ubiquitin.  Ubiquitin has seven embedded lysine residues to which an additional ubiquitin 
can be conjugated, allowing for the formation of ubiquitin chains and different patterns of 
linkages (Peng et al., 2003; Xu et al., 2009).  The importance of chain formation was 
recognized with the 2004 Nobel Prize in Chemistry, awarded for the discovery of ubiquitin-
mediated protein degradation.  The most recognized function of ubiquitin is that its chains 
can lead to protein degradation through the 26S proteasome (Elsasser and Finley, 2005; 
Saeki et al., 2002).   Despite this common understanding, not all chains and not all proteins 
tagged with ubiquitin are targeted for degradation.  The different chain lengths, target 
proteins, and types of linkages allow for a diversity in topology and therefore function.  
Like many PTMs, ubiquitin also has roles in regulating many cellular functions, including 
DNA repair, transcription, endocytosis, cell division, and apoptosis (Huang and D’Andrea, 
2006; Hurley et al., 2006; Mukhopadhyay and Dasso, 2007; Sokratous et al., 2014; Vucic 
et al., 2011).   
Deubiquitinating enzymes (DUBs) cleave ubiquitin from substrates and are 
responsible for generating new free ubiquitin molecules.  Through bioinformatics and 
experimental approaches, nearly 100 DUBs have been identified and they are subdivided 
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into five classes (Hanpude et al., 2015). Making up four of the five classes, the majority of 
DUBs are cysteine proteases, with the fifth class being metalloproteases. Four genes, 
ubiquitin B (UBB), ubiquitin C (UBC), ubiquitin A-52 residue ribosomal protein fusion 
product 1 (UBA52), and ubiquitin-40S ribosomal protein S27a (UBA80), serve as the 
source for generating new free ubiquitin. These genes are transcribed and translated as 
linear tandem ubiquitin fusions or as N-terminal fusions to other proteins. To become 
amenable for serving as a PTM, these ubiquitin fusion molecules are processed through 
DUB cleavage for cytosolic release.  Ubiquitin is recycled through the actions of a DUB.  
Integrated into the 26S proteasome that cleaves ubiquitin from proteins targeted for 
degradation. In the non-proteasomal setting, the reversible nature of ubiquitination 
becomes essential in tuning the activity, localization, and other functions of ubiquitin-
modified proteins.  DUBs can modify ubiquitin linear and branched chains that generate 
unique signals, thereby changing those signals and even rescuing proteins from degradation 
(Komander et al., 2009; Schrader et al., 2009).  While much research remains to be 
completed to achieve a more thorough understanding of the regulation of DUBs, it is clear 
that PTMs play an important role in the localization, stability, and activity of these 
enzymes.  Phosphorylation, ubiquitination, redox modification, and SUMOylation (a PTM 
to be addressed shortly) of DUB(s) have been observed and the functional consequences 
are beginning to emerge (Hanpude et al., 2015).  For example, phosphorylation of the DUB 
ataxin-3 occurs in one of its ubiquitin-interacting motifs (Mueller et al., 2009).  
Spinocerebellar ataxia type 3 (SCA3) is a neurodegenerative disease caused mutations in 
ataxin-3 which yield an expanded polyglutamine track in the protein and is associated with 
the accumulation of neuronal intranuclear inclusion bodies.  Phosphorylation of pathogenic 
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ataxin-3 controls ataxin-3’s stability, aggregation, and localization in a way that enhances 
its nuclear localization and formation of nuclear inclusions (Mueller et al., 2009). 
Ubiquitination of ataxin-3 at a specific lysine, K117, enhances ataxin-3’s DUB activity 
(Zhou et al., 2013).  In a third type of PTM that alters the disease status, ataxin-3’s stability 
and cytotoxicity is enhanced by a process called SUMOylation. 
3. SUMO 
 
Following the discovery of ubiquitin, other ubiquitin-like proteins (Ubls) were soon 
discovered.  They are designated as type I or type II based on whether they are conjugated 
to protein substrates (I) or not (II). These Ubls are typically small like ubiquitin (~10 kDa) 
and share a common structural fold consisting of a b-grasp domain of five antiparallel b-
strands partially wrapping an a-helix within a bbabbab secondary structure sequence 
(Bayer et al., 1998; van der Veen and Ploegh, 2012; Xu et al., 2009).  Today, there are a 
total of 17 type I Ubl proteins, broken down into eight known classes: SUMO, NEDD8, 
ATG8, ATG12, URM1, UFM1, FAT10, AND ISG15 (Cappadocia and Lima, 2017). 
Just over two decades ago, a Ubl was discovered and independently named by four 
separate labs.  Ultimately the name Small Ubiquitin-like Modifier (SUMO) has been 
commonly adopted (Boddy et al., 1996; Matunis et al., 1996; Okura et al., 1996; Shen et 
al., 1996).  Among the eight classes of type I Ubls, SUMO is the most pervasive and is 
conserved from yeast to mammalian cells (Chen et al., 1998).  SUMO and ubiquitin share 
48% structural fold similarity and 18% sequence homology (Figure 1-1A) (Bayer et al., 
1998; Wilson, 2009).  Though they share a similar fold, the surface of SUMO that contacts 
some of the essential enzymes in the SUMO pathway is more negatively charged than 
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ubiquitin (Figure 1-1B) and helps differentiate among the species that recognize the similar 
fold.  In the SUMO class of Ubls, there are four mammalian SUMO variants on separate 
genes, SUMO1, 2, 3, and 4 (Bohren et al., 2004; Kamitani et al., 1998).  SUMO1 shares 
46% identity and 66% homology with SUMO3 while SUMO2 and SUMO3 are nearly 
Figure 1-1 Sequence and structural surface comparison of ubiquitin and SUMO. 
A) Sequence alignment showing the similarity between ubiquitin and the four SUMOs.  Basic 
residues shown in magenta, acidic in blue, small hydrophobic (phenylalanine and tryptophan) 
in red, and the remainder (hydroxyl, sulfhydryl, amine, and glycine) in green. The lysine 
residue noted in SUMO2-4 is the residue SUMOylated in SUMO chains. Sequence Alignment 
completed using Clustal Omega: Larkin et al.  B) Electrostatic potential of ubiquitin (left) and 
SUMO1 (right) showing the face that interacts with their respective proteases (USP2 and 
SENP1 respectively).  PDB ID: 3V6E (left) 2IY1 (right).  In terms of vacuum electrostatics, 
red coloring indicates negative potential and blue indicates positive potential.  This negative-
positive coloring scheme correlates with the positive attributes of the University of Michigan 
(Go Blue!!) relative to its rival Ohio State. 
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identical with 92% identity and an absence of antibodies capable of distinguishing the two 
(Kamitani et al., 1998).  As a result, they are often referred to as SUMO2/3.  Notably, like 
ubiquitin, SUMO2/3 contain their own internal lysine residue capable of being modified 
by SUMO and thereby allowing for the formation of SUMO chains in vivo (noted in Figure 
1-1A (Tatham et al., 2001). SUMO1, 2, and 3 are expressed in all tissues that have been 
tested (Wilson, 2017). In contrast,  SUMO4, which shares 87% homology with SUMO2, 
is expressed primarily in the kidney, spleen, and lymph (Bohren et al., 2004; Guo et al., 
2004). Within the SUMO family, only SUMO2 is essential. Despite the similar identity 
between SUMO2 and SUMO3, SUMO3-deficient mice are viable whereas SUMO2-
deficient mice die at embryonic day 10.5 (Wang et al., 2014).  The difference in viability 
does not appear to be due to functional differences between the two SUMOs but rather a 
result of the difference in their unique expression pattern during embryonic development.  
Out of the three prominent SUMOs, SUMO2 makes up 75-80% of mRNA levels and 
SUMO3 only makes up 2-3% during embryonic development (Wang et al., 2014).  
SUMO1-deficient mice are viable and SUMO2/3 can compensate for loss of SUMO1 
(Evdokimov et al., 2008; Zhang et al., 2008).  
Like ubiquitin, SUMOs are translated as a precursor that must be proteolytically 
processed to expose the flexible C-terminal di-glycine motif (Figure 1-1A).  This is the 
mature form that is amenable to conjugation to substrate proteins.  This precursor 
processing is performed by a set of proteases called SENPs, which will be further described 
shortly.  Once processed to mature SUMO, conjugation of SUMO to substrate, termed 
SUMOylation, takes place via a set of dedicated E1, E2, and E3 enzymes that are similar 
in enzymology to those in the ubiquitin system (Figure 1-2).  There is one known E1 
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activating enzyme complex for the SUMO system, a heterodimer of SUMO activating 
enzymes 1 (SAE1) and 2 (SAE2) (Desterro et al., 1999; Gong et al., 1999).  In contrast to 
the ubiquitin system, there is only one known SUMO E2 conjugating enzyme, termed 
ubiquitin conjugating enzyme 9 (Ubc9) or ubiquitin conjugating enzyme E2I (Ube2I) 
(Johnson and Blobel, 1997; Watanabe et al., 1996).  Ubc9 is essential for development, as 
Ubc9-deficient mice are embryonic lethal, dying early after implantation (Nacerddine et 
al., 2005).  There are a handful of E3 ligase enzymes for SUMO, but unlike the 
Figure 1-2 SUMOylation pathway. 
The SUMO precursor protein is processed by a member of the SENP enzyme family (1) to 
generate a SUMO capable of adenylation by the SUMO E1 enzyme complex (SAE1/SAE2) 
and conjugation to its catalytic cysteine (2).  The SUMO is handed off to the SUMO E2 enzyme 
Ubc9 via transthioesterification to its cysteine residue and the E1 enzyme can cycle back to 
activate new SUMO molecules (3).  With the help of a SUMO E3 enzyme, SUMO is 
transferred from Ubc9 to its target substrate lysine (4) embedded within a SUMOylation motif.  
Reversal of SUMOylation is carried out by the SENP enzymes, which deconjugate 
(deSUMOylate) it from the target protein (5) and recycle the free SUMO to be used for 
subsequent rounds of SUMOylation. 
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ubiquitination pathway, they are not always necessary.  SUMOylation of target proteins 
can be achieved in vitro without the aid of an E3 ligase (Desterro et al., 1999; Okuma et 
al., 1999). SUMO E3 ligases, like protein inhibitor of activated STAT1 (PIAS1) and Ran 
binding protein 2 (RanBP2), generally enhance SUMOylation efficiency and specificity by 
bringing the SUMO-loaded Ubc9 and the SUMO-targeted substrate together or by aligning 
the SUMO for efficient conjugation without necessarily interacting with the substrate itself 
(Gareau and Lima, 2010; Kahyo et al., 2001; Pichler et al., 2002).  As a mechanism to 
bypass the E3 ligases, Ubc9 contains a surface near its active site cysteine that is able to 
bind the SUMOylation consensus motif in an independent manner (Bernier-Villamor et al., 
2002). 
The consensus sequence on substrate proteins for SUMOylation is yKxD/E and is 
often flanked by proline or glycine residues, suggesting a loop or unstructured region 
accompanies the SUMOylation motif (Iñiguez-Lluhí and Pearce, 2000; Mukherjee et al., 
2012; Sampson et al., 2001). In this consensus sequence, y represents a hydrophobic 
residue, K is the lysine containing the e-NH3+ group for isopeptide linkage to SUMO, x is 
any amino acid, and the motif ends with an acidic residue.  Despite this canonical motif, 
numerous proteomics studies have yielded alternative motifs as SUMOylation sites. 
Among these alternatives are an inverted SUMO motif (D/ExKy), which notably is found 
in SUMO1, an expansion of the preceding hydrophobic residues (yyyKxD/E), and motifs 
that include SUMOylation sites dependent on downstream negative charges through 
phosphorylated serines or acidic amino acids (Hietakangas et al., 2006; Matic et al., 2010; 
Yang et al., 2006).  With these sequences in mind, the best proteomics data puts the number 
of observed SUMOylated human proteins at 3,617 with 7,327 total SUMOylation sites and 
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a maximum of 63 sites on one protein, E3 SUMO-protein ligase zinc-finger 451 (ZNF451) 
(Hendriks and Vertegaal, 2016).  With its E3 ligase activity and E4 elongase activity, 
meaning it elongates SUMO chains, ZNF451 is thought to experience self-SUMOylation 
with the aid of its multiple SUMO-interacting motifs (SIMs) (Eisenhardt et al., 2015; 
Hendriks and Vertegaal, 2016).  The E2 conjugating enzyme Ubc9 has its own SUMO 
consensus motif that is essential to its function in modifying substrates with SUMO 
(Sampson et al., 2001). 
Like other PTMs, SUMO is reversible.  DeSUMOylation, or cleavage of the 
isopeptide bond between the substrate e-NH3+ group and the carboxyl group of mature 
SUMO’s terminal glycine, is performed by the previously mentioned SENP enzymes.  
With their name rooted in one of SUMOs original names, sentrin, these sentrin or SUMO 
proteases are a family of cysteine proteases that catalyze both the SUMO precursor 
processing and the removal of SUMO from its substrate.  There are six SENP enzymes, 
SENP1-3 and SENP5-7.  They share a common C-terminal catalytic domain containing the 
His and Asp residues as part of the catalytic triad essential for cysteine-mediated peptide 
hydrolysis but contain variable N-terminal domains (NTDs) that regulate their localization 
and specificity (Gong et al., 2000; Hang and Dasso, 2002; Kim et al., 2000; Nishida et al., 
2000, 2001).  The differences in localization, precursor processing (or endopeptidase 
activity), deconjugation (or isopeptidase activity), chain-editing (protease activity on 
SUMO chains) and SUMO paralog specificity are outlined in Table 1.2.1 (Hickey et al., 
2012; Kolli et al., 2010; Mendes et al., 2016; Mikolajczyk et al., 2007; Nayak and Müller, 
2014).   
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Table 1.2: SENP characteristics. 
 
	 Localization	 SUMO	preference	 Precursor	Processing	 deSUMOylation	
Chain	
editing	
	
SENP1	
	
Nuclear	pore,	
nuclear	foci,	
and	
cytoplasm	
SUMO1-3	 Yes	 Yes	 Yes	
	
SENP2	
	
Nuclear	pore,	
nuclear	foci,	
and	
cytoplasm	
SUMO2/3	>>	
SUMO1	 Yes	 Yes	 Yes	
	
SENP3	
	
Nucleolus	 SUMO2/3	 No	 Yes	 No	
	
SENP5	
	
Nucleolus	&	
Mitochondria	 SUMO2/3	 No	 Yes	 No	
	
SENP6	
	
Nucleoplasm	 SUMO2/3	 No	 Yes	 Yes	
	
SENP7	
	
Nucleoplasm	 SUMO2/3	 No	 Yes	 Yes	
 
 
Based on their characteristics, the SENP enzymes are further subdivided in to three 
groupings. SENP1 and SENP2 have the broadest substrate specificity in both precursor 
processing and isopeptidase activity across the SUMO family. They also contain a nuclear 
localization signal within their sequence, and SENP2 contains a nuclear export signal, 
allowing them to shuttle between the nucleus and cytoplasm (Bailey and O’Hare, 2004; 
Itahana et al., 2006). Making up the second subclass, SENP3 and SENP5 are nucleolar and 
prefer SUMO2/3 substrates. Lastly SENP6 and SENP7 form a group and have an extra 
conserved sequence insertions in their catalytic domains (Nayak and Müller, 2014). Both 
SENP1 and SENP2 are essential, as mice deficient in either are embryonic lethal (Cheng 
et al., 2007; Kang et al., 2010; Sharma et al., 2013).  In the management of SUMO1-
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modified proteins in mice, SENP1 is essential for deSUMOylation, including 
deSUMOylation of SUMO1-capped SUMO2/3 chains (Sharma et al., 2013).   While 
SENP1 is not essential for deSUMOylating SUMO2/3, as the other SENP enzymes can 
compensate, SENP1 itself is capable of being modified by SUMO2/3, though the 
functional consequences of this SUMOylation of SENP1 are unknown (Sharma et al., 
2013).  
Unlike SUMO1-3, SUMO4 is not processed by an SENP enzyme due to a proline 
residue found two residues upstream of the C-terminal Gly-Gly motif and is only processed 
by a stress induced hydrolase (Owerbach et al., 2005; Wei et al., 2008).  This lack of 
precursor processing because of SUMO4’s proline is, in part, likely due to the strict steric 
constraints of SENPs.  The catalytic cysteine in SENP enzymes sits under a narrow tunnel 
created by tryptophan residues (Figure 1-3).  This catalytic tunnel creates rigid specificity 
where only the small glycine residues are able to fit and the proline-induced limitation on 
secondary structure and phi and psi angles may prevent proper orientation.  In conjunction 
with the E1, E2, and E3 enzymes in the SUMO pathway, the SENP enzymes’ functions 
yield a framework for SUMO recycling and a PTM system with the plasticity that allows 
for dynamic regulation of cellular processes (Figure 1-2).  
4. SUMO Functions 
As a macromolecule, SUMO protein can exert its functions through a variety of 
ways.  Via SUMOylation, protein interactions with other proteins can become blocked by 
occlusion of the surfaces through which they form a complex.  In contrast, the new hybrid 
surfaces created on a SUMOylated protein can promote new protein-protein interactions.  
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Additionally, SUMOylation can perturb the tertiary structure of the protein it is modifying, 
thereby altering the conformation and exposing new interaction surfaces.  Lastly, SUMO 
functions can prevent modification of a SUMOylated lysine by other PTMs. Nearly a third 
of identified SUMOylation sites overlap with known methylation, acetylation, and 
Figure 1-3 SUMO – SENP1 complex. 
Crystal structure of SENP1 (blue surface) in complex with SUMO1 (orange ribbon).  The 
catalytic region is indicated by the arrow.  The catalytic cysteine is covered by the tryptophan 
tunnel.  The narrow tunnel is able to accommodate the size of the small glycine amino acids. 
PDB ID: 2IY1. 
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ubiquitination sites, with ubiquitin making up the majority of the sites (Hendriks and 
Vertegaal, 2016).  
To elaborate on one of the mechanisms listed above through which SUMO executes 
its function, protein-protein interactions introduced via SUMOylation are often facilitated 
by SUMO interaction motifs (SIMs).  Though these protein-protein interactions through 
SIMs are weak, ~1-100 µM, they have been found on many E3 ligases and other proteins, 
sometimes with numerous SIMs being found on one protein (Hecker et al., 2006; 
Keusekotten et al., 2014).  Found on the surface of interacting proteins, SIMs are made up 
of a series of three to four hydrophobic residues and are typically followed by a series of 
acidic amino acid residues that vary in length (Hannich et al., 2005; Hecker et al., 2006; 
Kaur et al., 2017; Minty et al., 2000; Song et al., 2004).  Together this string of residues 
forms a b-strand that forms an intermolecular beta-sheet with the b2 strand of SUMO and 
interlaces between this b2 strand and the a1-helix of SUMO.  Notably, this region of SUMO 
is one of the regions where the sequences of the SUMO isoforms differ substantially and 
could drive some of the selectivity they exhibit between SUMO isoforms and their 
functional effects (Huang et al., 2004).  Within the series of hydrophobic residues, there is 
often an acidic residue interrupting it.  Additionally, serine and threonine residues are 
frequently found within the series of acidic residues and/or within the hydrophobic series.  
These additional features help further guide the selectivity and orientation of the SIM-
containing protein to SUMO paralogs (Chang et al., 2011; Hecker et al., 2006; Kaur et al., 
2017; Namanja et al., 2012; Song et al., 2005).  The acidic amino acid series helps orient 
the SUMO-SIM interaction, dictating whether the b-strand of the SIM runs parallel or 
antiparallel to the b2-strand in SUMO.  The serine and threonine residues are potential 
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phosphorylation sites and are important for preferential binding of SUMO1 over SUMO2.  
The non-conserved N-terminal domains (NTDs) of SENPs contain one or more SIMs to 
possibly recruit SUMO, but the SUMO binding surface that SENPs ultimately engage with 
for catalysis is distinct from the SIMs and covers a larger surface area than the E1 and E2 
enzymes (Hickey et al., 2012; Kerscher, 2007; Komander et al., 2009; Namanja et al., 
2012).  Counter to the SIM surface is the specific surface on SUMO that interacts with the 
SIMs.  Previously, our lab systematically examined the residues on the SUMO2 surface 
for functional inhibition of transcription (Chupreta et al., 2005).  Among the seven residues 
on SUMO identified in altering SUMO-mediated inhibition, four were positively charged.  
These seven residues are found on the second beta-strand and the alpha helix following it 
and are in agreement with the SIM-focused work described above.  The location of the 
surface on SUMO2 that interacts with SIMs is opposite (180°) to the face that interacts 
with Ubc9 and SENP enzymes.   
 As might be expected for a PTM that potentially modifies nearly a fifth of the 
human proteome, the roles of SUMO in cellular function are extensive.  Unlike most other 
PTMs, SUMOylation occurs predominantly in the nucleus where the SUMOylation 
machinery is typically found (Rodriguez et al., 2001; Zhang et al., 2002).  Although 
SUMO’s name is rooted in its similarity to ubiquitin, SUMOylation has wider-ranging 
functions than ubiquitin.  In a macroscopic perspective, SUMO proteomics studies have 
revealed that there are functional clusters of SUMOylated proteins.  These clusters include 
proteins involved in the DNA damage response, pre-mRNA splicing, ribosomal 
biogenesis, cell cycle regulation, transcriptional regulation, and chromatin remodeling 
(Hendriks and Vertegaal, 2016).  Because of the promiscuity and lack of diversity in 
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SUMO E1, E2 and E3 enzymes with respect to the broad functional consequences of 
SUMOylation, the specificity of SUMOylation targets and functional outputs is thought to 
be driven by the clustering of proteins collectively responsible for specific categories of 
tasks (Hendriks and Vertegaal, 2016; Psakhye and Jentsch, 2012).  Essentially, with only 
one identified E1 and E2 enzyme, specificity is supported by locally concentrated 
substrates for group modification. 
Working down from proteomics to a more specific functional perspective, SUMO 
is intimately involved in DNA damage response pathways. DNA damage in terms of G-
U/T mismatch or methylated cytosine is repaired in part by thymidine DNA glycosylase 
(TDG).  After performing the first step of generating an abasic site in the DNA via 
hydrolysis of the N-glycosidic bond between the base and the deoxyribose, TDG must 
dissociate from the DNA. This dissociation is the rate-limiting step of its function. As an 
example of SUMOylation-induced conformational change, after base excision, 
SUMOylation of TDG generates a conformational change.  This SUMOylation reduces the 
severe product inhibition on TDG by abasic sites and induces dissociation of its 
glycosylation domain from the DNA backbone while retaining active site integrity and 
glycosylation function (Steinacher and Schär, 2005; Waters et al., 1999).   This aided 
dissociation creates a significant increase in enzymatic turnover and enhances the effects 
of enzymes involved in the next steps of base-excision repair (Hardeland et al., 2002; Smet-
Nocca et al., 2011).  
When double strand DNA breaks arise and repair occurs via homologous 
recombination (HR), SUMO is again involved, this time modifying a large cluster of 
proteins.  The process of HR is multi-stepped and involves the initial identification and 
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stabilization of the ends of the free DNA, formation of single-stranded DNA by nucleases, 
capping of ssDNA, homology searching, and recombination and annealing to complete the 
repair.  Throughout this process numerous proteins are involved, including replication 
protein A (RPA), Rad52, and Rad59, and the majority of them are SUMOylated (Cremona 
et al., 2012; Dou et al., 2010; Psakhye and Jentsch, 2012).  In the same group-style 
modification mentioned earlier, DNA damage induces a wave of SUMOylation that 
enriches with the proteins involved in HR (Psakhye and Jentsch, 2012).  Supported by the 
observance of little to no effect of involved single-protein SUMOylation mutants on HR, 
the comprehensive SUMOylation profile on the family of proteins involved in HR is key, 
allowing for synergy among the SUMO modifications (Ohuchi et al., 2008; Psakhye and 
Jentsch, 2012).  
In addition to the effects SUMO has in mediating the activity and function of 
proteins directly involved in HR, SUMO also plays a role in recruiting ubiquitin E3 ligases 
for regulation of turnover of proteins involved in HR.  SUMO-targeted ubiquitin ligases 
(STUbL) are a set of ubiquitin E3 ligases that recognize SUMO and through their 
interaction with SUMO, ubiquitinate the target protein. RNF4 is a STUbL that has four 
SIMs that can recognize both a series of individual SUMOylations or SUMO chains 
(Keusekotten et al., 2014).  In response to DNA double strand breaks in humans, RNF4 is 
recruited through its SIMs to ubiquitinate proteins involved in the repair cascade, including 
RPA and MDC1, and target them for proteasomal degradation (Galanty et al., 2012; Vyas 
et al., 2013).  Additionally, the SUMO-ubiquitin chains created by RNF4 allow for further 
recruitment of SIM-containing proteins in the BRCA1-A complex which is involved in 
following steps of DNA damage repair (Guzzo et al., 2012).   
 19 
In direct opposition to the action of RNF4, ubiquitin specific protease 11 (Usp11) 
is a DUB that interacts with RNF4 and is targeted specifically to hybrid ubiquitin-SUMO 
chains (Hendriks et al., 2015).  In undoing the action of RNF4, Usp11 removes the 
ubiquitin polymers from SUMO chains, thereby forming a mechanism to balance the 
modification and resulting function of the modified protein.  In another example of a 
SUMO deubiquitinase, Usp7 is a DUB present in the chromatin around replisomes.  Mature 
chromatin is ubiquitin rich and SUMO poor, but in the replisome the inverse occurs via the 
action of Usp7 on ubiquitin modified SUMO2 chains (Lecona et al., 2016).    
While SUMO and ubiquitin can work in concert as described above, they can also 
compete with each other for lysine residues on target proteins.  Among the best-
characterized examples is the competition between ubiquitination and SUMOylation on 
Lys21 of the protein IκBα. As an inhibitor of NFκB activity, IκBα complexes with NFκB 
in the cytoplasm and activation of NFκB involves ubiquitination and subsequent 
degradation of IκBα.  When IκBα is SUMOylated, it is unable to be ubiquitinated and 
allows for continued repression of NFκB-dependent transcription (Desterro et al., 1998).  
As an additional layer of cross-talk among PTMs, IκBα phosphorylation is required for its 
ubiquitination whereas this prevents its SUMOylation. Despite elucidation of SUMO cross 
talk and competition with other PTMs and point mutants generating further understanding, 
there remains much to be understood regarding the complex functional consequences 
surrounding SUMO. 
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5. SUMO and Transcription 
 
Among the many cellular functions in which SUMO interjects is in transcriptional 
regulation.  It is also among the earliest studied functions of SUMO and has a positive 
reputable history in our laboratory.  With transcription occurring in the nucleus, it is worth 
noting that nearly 80% of proteins known to be a part of nuclear complexes are SUMO 
targets (Hendriks et al., 2017).  Regulation of transcription by SUMO includes effects on 
both transcription factors (TFs) and co-regulators in the nucleus. Additionally, this 
regulation extends beyond the nucleus, interfering with processes coordinating 
transcription factor activation or degradation in the cytosol.  As a result of the essential 
nature of transcription and effects of SUMO in manipulating it, there have been numerous 
efforts to elucidate the details of SUMO’s role in transcription. 
In the assembly of the pre-initiation complex for transcription, co-regulators are 
proteins that do not directly bind to the DNA and instead bind to and link the transcription 
factors and RNA polymerase to tune transcriptional output.  Co-regulators can act as either 
co-activators or co-repressors and can be modified by SUMO to disrupt their function or 
recruit other co-regulators.  Many co-regulators have been identified as SUMO targets, 
including nuclear receptor co-repressor (N-CoR), p300 co-activator, peroxisome 
proliferator-activated receptor g coactivator 1a (PGC-1a) and receptor-interacting protein 
140 (RIP140) (Girdwood et al., 2003; Rytinki and Palvimo, 2008, 2009; Tiefenbach et al., 
2006; Treuter and Venteclef, 2011).  Depending on the co-regulator and its assigned 
function, SUMOylation can enhance a co-repressor’s repression, de-repress a co-repressor 
to stop its function, repress a co-activator or prevent its binding, and still in others it can 
recruit other co-regulators that repress transcriptional activity.  In the case of p300, it 
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typically helps activate transcription through its histone acetyltransferase (HAT) activity, 
but SUMOylation of p300 antagonizes this function.  SUMOylation of p300 recruits 
histone deacetylase 6 (HDAC6) which reverses acetylation by p300.  This deacetylation 
condenses DNA nucleosomes and represses transcription by p300 (Girdwood et al., 2003).   
In addition to co-regulators, TFs are also SUMO targets.  Recent Gene Ontology 
analysis of SUMO proteomics suggests that nearly 300 DNA-binding TFs are SUMO 
targets, representing over 50% of all TFs (Hendriks et al., 2017; Rosonina et al., 2017).  
The general understanding of the field is that SUMOylation of TFs reduces transcription 
of their target genes.  Most examples of SUMOylation of TFs yield an inhibitory effect on 
transcription.  Yet there are a few exceptions to this reduction as well as examples of 
contradictory observations that cloud the understanding of the effects of SUMO on the 
same TF (Berta et al., 2007; Cheng et al., 2007; Chymkowitch et al., 2015; Gill, 2005; Lyst 
and Stancheva, 2007).  To use the transcriptional co-activator p300 in an example again, 
SUMOylation of the TF Bcl11b fosters its interaction with p300.  In this case, 
SUMOylation and the presence of p300 causes HAT-driven decondensation of chromatin, 
relieving the repression of Bcl11b target genes (Zhang et al., 2012).  As another example 
of SUMO-mediated activation of transcription (but without implication of a co-regulator), 
activation of the Hedgehog pathway results in SUMOylation of the TF Gli1 (Cox et al., 
2010).  Under conditions where the Hedgehog pathway is not activated, Gli TFs are 
phosphorylated and subsequently ubiquitinated for proteasomal degradation (Jiang, 2006).  
Gli1 SUMOylation limits its phosphorylation and ubiquitination (including overlapping 
targeted lysine residues between SUMO and ubiquitin), lifting the restraints on Gli activity 
and essentially enhancing relative Gli1-mediated transcription.  Regarding contradictory 
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observations, in some cases SUMOylation of the TF hypoxia inducible factor-1a (HIF1a) 
has reduced its transcriptional activity yet in others it reduces its activity and leads to its 
degradation (Berta et al., 2007; Cheng et al., 2007).  Hypotheses concerning these types of 
poorly understood SUMO-effects suggest that there may be tissue specific or other 
condition specific components tuning SUMO function on TF activity.  Nevertheless, the 
profound impact SUMO has on transcription provides the continued motivation to study 
and understand the intricacies despite confounding results. 
6. SUMO and Nuclear Receptors 
 
Nuclear receptors (NRs) are a superfamily of transcription factors that bind 
sequence specific promoter elements on target genes.  The 48 known NRs in the human 
genome are subdivided into six evolutionary groups, and half of all NRs have known 
ligands (Germain et al., 2006).  All NRs consist of a modular structure of five to six 
domains labeled A through F (Figure 1-4A).  Working from the C-terminus, the E/F 
domain consists of the ligand-binding domain (LBD).  The LBD mediates ligand binding, 
receptor dimerization on the DNA response elements, and ligand-dependent transactivation 
through its activation function 2 (AF-2) helix.  Upon ligand binding, the AF-2 helix surface 
becomes accessible for co-regulator recruitment and binding (Figure 1-4B).  The D domain 
is a poorly conserved hinge region between the LBD and the C-domain and it can contain 
a nuclear localization signal (NLS).  The C-domain, or DNA-binding domain (DBD) is 
found in all but two NRs and is responsible for binding to specific DNA sequences, termed 
hormone response elements (HREs).  Composed of two cysteine-rich zinc finger motifs 
and two alpha helixes, the DBD is highly conserved and also participates in receptor 
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dimerization (Germain et al., 2006).  The N-terminal A/B region is poorly conserved across 
the superfamily and contains a transcriptional activation function (AF-1).  AF-1 is able to 
function autonomously, allowing for constitutive activity even in ligand-dependent NRs.  
The highly variable A/B domain is the target of many PTMs but its structure in any NR 
has yet to be elucidated.   
Figure 1-4 Nuclear receptor organization. 
A) General domain organization for nuclear receptors from amino to carboxyl-terminus. AF-
1 and AF-2 are short for activation function 1 and 2, with the other abbreviations noted.  AF-
1 is part of the larger A/B domain, with the other individual domains color-coded and labeled.  
B) Crystal structure of the ligand-binding domain (LBD) of the androgen receptor bound to 
one of its agonists, dihydrotestosterone (DHT).  Helix 12 (red) is essential for the AF-2 
function. 
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Like SUMO, NRs play an essential role in nearly all aspects of mammalian 
physiology and their regulation is necessary to maintain homeostasis.  Modification of NRs 
by SUMO to alter their localization, stabilization, DNA binding, and/or function is a 
mechanism for regulation of NRs and ultimately their transcriptional output.  Peroxisome 
proliferator-activated receptor (PPAR) a is a NR that modulates metabolism regarding 
lipid homeostasis and has its transcriptional activity enhanced by binding of co-activators 
such as p300 or steroid receptor coactivator 1 (SRC1).  SUMOylation of PPARa generates 
a new surface for docking with N-CoR to repress target gene transcription (Pourcet et al., 
2010).   
As one of the six NR groups, the steroid receptor family of NRs includes the 
glucocorticoid receptor, estrogen receptors, and androgen receptor.  It was in the 
glucocorticoid receptor (GR) that synergy control motifs, which ultimately became known 
as SUMOylation motifs, were discovered by our group.  In the A/B N-terminal domain 
(NTD) of GR, a motif within a negative regulatory region was identified to disrupt the 
transcriptional synergy that occurs when GRs bind to their multiple HREs at a gene 
promoter (Iñiguez-Lluhí and Pearce, 2000).  Compared to a single HRE where one NR 
dimer can bind, these multiple HREs, termed compound response elements, allow for 
recruitment of multiple NR dimers.  The transcriptional output in response to multiple 
steroid receptors binding is more than just the additive effect of a single steroid receptor 
HRE binding, but instead amplifies the output, due to synergy between the individual 
receptors.  Synergy control (SC) motifs limit the scope of this synergy, allowing for tuning 
of the magnitude of transcriptional response.  Mutation of these motifs disrupts the 
repressed synergy without disrupting DNA binding, but only at compound HREs.  These 
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SC motifs were found in other steroid receptor NRs in their NTD and in other TFs, with 
different numbers of copies in each (Danciu et al., 2012; Iñiguez-Lluhí and Pearce, 2000).  
Figure 1-5 AR SUMOylation and transcriptional consequences. 
A) Domain organization of androgen receptor (AR) with the synergy control (SC) motifs and 
the SUMO-targeted lysine within them in red.  AF-1 = Activation Function 1, (Q)24 designates 
the location of the polyglutamine tracks in AR, DBD = DNA binding domain, LBD= ligand 
binding domain. B) Immunoblot of AR immunoprecipitates from 293T cell extracts 
transfected with HA-tagged SUMO3 and with either WT AR or AR with a double lysine 
mutant in the SC motifs (K385/518R). Cells were treated with agonist for 24 hours before 
lysis.  Blots for SUMO or AR are designated and the SUMOylated AR species designated with 
arrows.  C) Normalized reporter assay-based transcriptional activity at compound AREs (4 
ARE binding sites in this example) from cells transfected with vector plasmid, WT AR, or AR 
double lysine mutant in the presence of synthetic androgen (R1881) or vehicle.  Inset to show 
expression levels of WT and mutant AR.  D) Luciferase reporter assay based transcriptional 
activity of WT and double lysine mutant AR in the absence of agonist as a function of the 
amount of plasmid transfected.  Adapted in part from Mukherjee et al. 2012. 
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The androgen receptor (AR) is one of those steroid receptor NRs with SC motifs.   
The SC motif sequence consists of a core of a branched, aliphatic residues in the 
first position and a critical lysine then glutamate in the second and fourth positions. 
Flanking this core is a proline or glycine residue located a few residues upstream and 
downstream of the SC core (Iñiguez-Lluhí and Pearce, 2000; Mukherjee et al., 2012).  It 
was ultimately discovered that SC motifs align with the SUMOylation consensus motif and 
the lysine in the SC motif is indeed a SUMO target (Holmstrom et al., 2003; Poukka et al., 
2000; Subramanian et al., 2003).  Just as loss of the critical lysine in SC motifs abrogates 
their transcriptional repression in vitro, there are diseases related to the functional 
consequences of SC motif disruption. 
The androgen receptor (AR) has two SC motifs in its A/B NTD that serve as 
SUMOylation sites (Figure 1-5).  In Kennedy disease, also known as spinal and bulbar 
muscular atrophy (SBMA), there is a polyglutamine expansion within the AR NTD. This 
leads to misfolding, aggregation, and oligomerization of AR, causing lower motor neuronal 
toxicity.  Our group has shown that SUMOylation of these polyQ ARs can limit the 
pathogenic AR aggregation, giving SUMO a role in disease beyond transcriptional effects 
(Mukherjee et al., 2009). 
The proline and glycine amino acids that are upstream and downstream of both SC 
motifs in AR have been identified for mutation in numerous conditions implicated in AR 
biology, including degrees of androgen insensitivity syndrome (AIS) and associated 
oligospermia, infertility, and micropenis (Bhangoo et al., 2010; Ferlin et al., 2006; Hiort et 
al., 2000; Mukherjee et al., 2012).  These mutations lead to reduced SUMOylation of AR 
and induction of endogenous AR target genes (Mukherjee et al., 2012).  Mutations and 
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deletions in this flanking SC motif region and the SUMO targeted lysine have also been 
implicated in prostate cancer (Hyytinen et al., 2002; Mukherjee et al., 2012; Robinson et 
al., 2015).   
7. SUMO and Prostate Cancer 
 
Prostate cancer is the most common cancer diagnosed in men, making up nearly 
20% of all male cancer diagnoses (Siegel et al., 2017).  Although the rate of incidence is 
declining, in part due to more accurate diagnoses, approximately 1 out of every 8 men will 
be diagnosed with prostate cancer within his lifetime, creating a significant societal burden 
and resulting in it being the third leading cause of male cancer death.   
 At the center of prostate cancer is the androgen receptor.  This nuclear receptor 
resides in the cytosol when inactive and binds androgens such as testosterone and its higher 
affinity ligand dihydrotestosterone (DHT) (Figure 1-6).  Upon activation, it enters the 
nucleus via the nuclear localization signal found in the hinge region between its DBD and 
LBD.  AR dimerizes and binds to androgen response elements (AREs) on the DNA to help 
activate transcription of genes essential to normal male sexual development and bone, 
muscle, and fat metabolism.  In prostate cancer, this system is hijacked by oncogenes and 
AR is at the center of the disease.  In 1941, Huggins and Hodges first discovered the role 
of androgen signaling in prostate cancer by demonstrating that surgical castration or 
androgen ablation therapy provided palliative effects in patients with metastatic prostate 
cancer (Huggins and Hodges, 1941; Huggins et al., 1941).  This forms the basis of most 
prostate cancer therapeutics today, including androgen deprivation therapy (ADT), 
antiandrogen treatment, and inhibition of cytochrome p450 enzymes involved in steroid 
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hormone synthesis.  In ADT, gonadotropin releasing hormone (GnRH) agonists or 
antagonists are administered to eliminate GnRH pulses and instead generate a constant 
release or absence of the hormone (Tolis et al., 1982).  This ultimately inhibits synthesis 
Figure 1-6 Androgen receptor signaling pathway. 
The androgen receptor (AR) resides in the cytosol in complex with heat shock proteins (HSP) 
chaperones.  Ligand binding by androgens, dihydrotestosterone (DHT) in this example, 
displaces the HSPs, leading to activation of AR.  AR dimerizes and translocates to the nucleus 
where it binds to specific DNA sequences, termed androgen response elements (AREs). DNA 
binding leads to recruitment of AR co-regulators and proteins of the general transcription 
machinery, including RNA polymerase II (RNA Pol II), to initiate transcription of the 
respective DNA. 
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of androgens in the testes, yielding castrate levels of circulating androgens by chemical 
means.  Common AR antagonists occlude access to the LBD by androgen agonists to limit 
AR activation.  Prostate cancer cells have also been shown to upregulate the enzymes 
involved in steroid hormone synthesis to allow for enhanced localized levels of androgens 
for increased AR signaling despite castrate levels in the serum (Cai and Balk, 2011; 
Montgomery et al., 2008; Nishiyama et al., 2004; Stanbrough et al., 2006; Titus et al., 
2005).  Abiraterone acetate is a third type of therapeutic for PC that targets cytochrome 
p450 17A1 to inhibit localized prostatic synthesis directly. 
 While these therapies listed above do provide initial involution of both healthy and 
cancerous prostatic tissue, approximately 80-90% of the patients relapse after 18-36 
months through a variety of mechanisms in which AR has garnered the ability to maintain 
signaling despite the attempts to limit its activation (Chuu et al., 2011; Pienta and Bradley, 
2006).  These mechanisms include: 
1. overexpression of AR to increase the receptor reserve and androgen sensitivity,  
2. mutations in the LBD that create promiscuity in agonists to activate the receptor 
(both therapeutic antagonists and other steroid hormones),  
3. alternative signal activation by other signaling proteins,  
4. AR bypass by other TFs including glucocorticoid receptor activation which has a 
highly overlapping cistrome with AR, and  
5. increased constitutive activity which can be a result of alternative splice forms of 
AR where the LBD is absent (Arora et al., 2013; Dehm et al., 2008; Guo et al., 
2009; Hara et al., 2003; Hu et al., 2009; Sun et al., 2010; Suzuki et al., 1993; Tan 
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et al., 1997; Veldscholte et al., 1990; Visakorpi et al., 1995; Watson et al., 2015; 
Wijngaart et al., 2010; Zhao et al., 2000).   
Despite all these resistance mechanisms, AR remains at the center of the proliferative drive 
of the disease in the majority of patients (Chandrasekar et al., 2015; Kahn et al., 2014).  At 
this advanced stage, when the disease no longer appropriately responds to the three types 
of therapies identified above, it is identified as castration resistant prostate cancer (CRPC).   
While there are some therapies that exist beyond this stage, they are not curative and only 
temporarily extend survival by a few months.  There is a need for new alternative therapies 
to address this deadly, advanced disease and targeting the SUMO pathway is among those 
efforts being employed. 
 As mentioned previously, SUMOylation of AR limits its transcriptional activity at 
compound AREs (Figure 1-5).  With respect to the resistance mechanisms in CRPC listed 
above, AR SUMOylation is able to limit AR transcription in the context of both agonist 
activation and constitutive receptor activation, making the SUMO pathway an attractive 
target for novel therapeutics.  Notably, unlike other nuclear receptors, the hormone-
independent AF-1 of AR is stronger than its ligand induced AF-2 function in stimulating 
transcription (Ikonen et al., 1997; Moilanen et al., 1997).  Existing clinical and biochemical 
data on prostate cancer further support that aberrations in the SUMO pathway that reduce 
AR SUMOylation are a way to leverage AR activity for cancer cell proliferation. 
 The AR is primarily modified by SUMO1 among the SUMO isoforms and SENP1 
is the primary SUMO protease responsible for deSUMOylating AR (Kaikkonen et al., 
2008).  SENP1 is overexpressed in prostate cancer and can actually induce prostatic 
intraepithelial neoplasia, also known as PIN, a stage that precedes the development of 
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normal prostate epithelia to cancerous tissue (Bawa-Khalfe and Yeh, 2010; Bawa-Khalfe 
et al., 2010; Cheng et al., 2006).  In addition, SENP1 expression is induced by AR activity 
as an androgen responsive gene (Bawa-Khalfe et al., 2007).  With SENP1 as a positive 
modulator of AR activity via its deSUMOylation function, a positive feedback loop is 
generated between these two species to further the proliferative drive of the cancerous 
tissue, fostering prostate cancer progression and metastasis (Figure 1-7) (Wang et al., 
2013).  Interestingly, genes related to the cell cycle and cellular movement, death, 
proliferation, and development are differentially regulated between SUMOylated and non-
SUMOylated AR, with the non-SUMOylated form showing an enrichment in these gene 
Figure 1-7 Summary of SUMO-AR-SENP1 interactions in prostate cancer. 
When AR is SUMOylated (top) its transcriptional activity is inhibited, which limits AR’s 
ability to activate transcription of genes involved in the growth of prostate cancer cells.  Loss 
of SUMOylation on AR is performed by SENP1 and this generates the more active 
deSUMOylated form of AR to promote prostate cancer growth.  One of the gene targets of AR 
is the gene for SENP1, creating a positive feedback loop where overexpression of SENP1 leads 
to enhanced AR activity, sustaining further SENP1 expression.  Figure design by Jorge 
Iñiguez-Lluhí. 
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targets (Sutinen et al., 2014).  In agreement with the role of overexpressed SENP1 in 
prostate cancer, knockdown of SENP1 via siRNA has been shown to attenuate expression 
of AR target genes while slowing prostate cancer cell growth and inducing senescence in 
cell culture (Kaikkonen et al., 2008).  In patient cohorts, overexpression of SENP1 was 
associated with an array of characteristics indicating unfavorable disease outlook, 
including decreased biochemical recurrence free survival, increased tumor cell 
proliferation, higher Gleason score, positive ERG fusion status, PTEN deletion, and 
positive lymph node status (Burdelski et al., 2015; Li et al., 2013). 
 With strong clinical and biochemical target validation, SENP1 is an attractive drug 
target for new therapeutics in prostate cancer.  In addition, crystal structures of the catalytic 
domains of the SENP family of enzymes allow for improved molecular modeling in drug 
development.  Notably, with the SENP enzymes functioning as cysteine proteases, cysteine 
protease inhibition has been successfully approved for cancer therapy in terms of the 
proteasomal inhibitor bortezomib.  In contrast to the current armamentarium of 
therapeutics, the SUMO1/SENP1 system functions at the NTD of AR, rather than through 
the LBD where existing observed mechanisms of resistance reside.  Together, these 
attributes make SENP1 a novel, promising target for new prostate cancer therapeutics.  
Through high throughput screening and detailed kinetic characterization, the objective of 
this thesis work was to identify and study small molecule inhibitors specific to SENP1 for 
development of potential therapeutic scaffolds and probes to study the SUMO/SENP 
system and its regulation of activity.  
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Chapter 2  
 
Generation of a robust FRET-based assay for high throughput 
screening and characterization of SENP enzymes 
1. Introduction 
 
SUMO and the components involved in SUMOylation and1 deSUMOylation 
process are frequent targets of study because of their important roles in most cellular 
processes.  The embryonic lethality in mice of E2 Ubc9, SUMO2, SENP1, and SENP2 
knockouts supports the notion that dynamic SUMO modification is essential for exquisitely 
modulating protein activity in development and beyond (Nacerddine et al., 2005; Wang et 
al., 2014; Sharma et al., 2013; Kang et al., 2010).  These characteristics and the novelty of 
the SUMO system with its short two decades since discovery mean that several groups 
have generated an array of tools attempting to study the system. 
Highlighted in chapter 1, the family of SUMO proteases, known as SENPs, have 
been of particular interest due to their role in numerous cancers (Eifler and Vertegaal, 
                                                
‡ Many of the experiments in this dissertation were carried out with participation of 
multiple individuals. For each relevant chapter, the contributions are indicated in a footnote 
in the first page of each chapter. Carrie M. Johnson performed the assay condition 
optimization and kinetic characterization. Carrie M. Johnson performed the substrate 
characterization and assay performance in collaboration with Dr. Jorge Iñiguez-Lluhí. The 
substrate design expression and purification were carried out by Dr. Jorge Iñiguez-Lluhí.  
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2015).  Because of the similarities to ubiquitin, many of the tools used to study 
deubiquitinating enzymes were adapted for the SUMO system.  One of the earliest tools 
uses a hemagglutinin (HA) tagged SUMO with a vinyl sulfone (VS) moiety attached to the 
Gly-Gly C-terminal SUMO tail. When in proper proximity and confirmation, the VS group 
forms a covalent adduct with the catalytic cysteine of the SENP enzyme. This irreversible 
inhibitor can be used to probe the different SENPs for their preference for the SUMO 
isoforms. SUMO-AMC is a fluorogenic substrate where the C-terminal glycine residue of 
SUMO is conjugated to 7-amino-4-methylcoumarin (AMC).  When still conjugated to 
SUMO, the intrinsic fluorescence of AMC is quenched.  SENP enzymatic activity cleaves 
AMC from SUMO, releasing AMC and increasing the fluorescence of the system at 460 
nm and allowing measurement of SENP activity using steady state kinetics (Kolli et al., 
2010; Madu and Chen, 2001).     
Like SUMO-AMC, the C/EBP homologous protein (CHOP)-reporter platform 
links SUMO and another chemical moiety, this time an enzyme, phospholipase A2 (PLA2).  
Attached at its amino-terminus to the C-terminal glycine residue of SUMO, PLA2 is an 
enzyme that only functions when its N-terminus is free (Nicholson et al., 2008).  Only upon 
cleavage and release from SUMO by SENP protease activity does the PLA2 become active.  
Acting as a reporter enzyme, PLA2 is able to cleave its substrate NBD C6-HPC and generate 
the fluorescent product, NBD, to generate a detectable, quantitative fluorescent readout of 
SENP activity  (Leach et al., 2009).  Alternatively, because PLA2 is an enzyme of 
approximately 14 kDa, a gel based approach monitoring the shift in molecular weight of 
the starting SUMO-CHOP construct to free SUMO and free PLA2 can be used instead of 
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fluorescence.  In this format, no PLA2 substrate is needed but the assay has lower 
throughput.   
In a different kind of gel-based approach, SUMO-conjugated Ran GTPase-
activating protein (RanGAP) is used to study SENP isopeptidase activity.  Unlike the linear 
SUMO-based tools that rely on SENP endopeptidase activity, this system requires more 
effort to generate the substrate by combining SUMO, the SUMO E1 and E2 enzymes, and 
the SUMO target protein, RanGAP. Once SUMOylation is achieved, the SUMO-RanGAP 
substrate can be incubated with a SENP enzyme and the reaction can be killed via addition 
of SDS sample buffer at different time points or in a dose responsive manner and run on a 
gel for general quantitation. 
In a bioluminescent approach to study SENP activity, a commercially available 
SENP substrate of carboxybenzyl-Arg-Leu-Arg-Gly-Gly-luciferin is used to assess 
protease activity.  Alternatively, an amino-luciferin (AML) analog of this substrate 
provides further sensitivity from the original luciferin substrate (Orcutt et al., 2012).  The 
SENP enzyme recognizes the Gly-Gly sequence and cleaves the peptide bond after the 
second glycine residue to release free luciferin.  Luciferin is a substrate for the enzyme 
luciferase, and generating the bioluminescent substrate oxyluciferin.  Though this reporter 
enzyme system, the bioluminescence approach has the advantage of improved sensitivity 
and wider dynamic range over substrates with a quenched fluorophore conjugated to the 
peptide C-terminus like SUMO-AMC (Leippe et al., 2011).  In testing for inhibitors, this 
approach also avoids issues related to fluorescence interference by test compounds.  
However, as a small peptide substrate, this system does not allow for differentiation among 
the SUMO isoforms.  It also misses the important contributions the globular portion of 
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SUMO has in contact with SENPs and yields kinetic parameters orders of magnitude 
different from those determined using full length SUMO (Chen et al., 2014). 
Fluorescence resonance energy transfer (FRET) assays have been adapted for the 
SUMO/SENP system.  The FRET system for studying the SENP enzymes has experienced 
a series of improvements to enhance FRET efficiency and quantitation of SENP kinetics.  
The substrate has been optimized to generate better FRET efficiency and quantum yield 
and the cross contamination of fluorescent signal had been accounted for, but shortcomings 
remain (Jiang et al., 2013, 2014; Liu and Liao, 2013; Liu et al., 2012, 2015, Martin et al., 
2007, 2008).  Despite the availability of several assay formats for SENP1, for the most 
part, the assays have been used in a semi-quantitative manner without conversion to actual 
substrate or product concentration values and without applying a rigorous enzyme kinetic 
analysis.  Of key significance, SENP enzymes utilize a large exosite for recognition away 
from the active site and are thus expected to be subject to significant product inhibition. 
However, no satisfactory consideration has been given to this process in the existing 
literature, which can severely influence estimation of kinetic parameters and mechanism 
of action of inhibitors.  Given the interest in the potential therapeutic applications of SENP 
based therapeutics, a successful drug discovery and development program depends 
critically on a robust and well-validated assay pipeline.  Robust, scalable and high 
throughput ready assays are essential for hit identification and validation whereas 
quantitative detailed kinetic characterization assays are indispensable for defining the 
properties of the enzyme and the mechanism of action of inhibitors.  Recognizing these 
needs and the shortcomings of existing platforms, our group has generated and 
characterized in detail a set of evolved FRET-based SENP substrates that can be used to 
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monitor the peptidase activity of SENP and can be readily obtained in high yield.  We have 
used them to develop robust, miniaturized and facile ratiometric assays for high-throughput 
screening and selectivity assessment.  By leveraging our detailed characterization of the 
substrates, we have also developed a wide dynamic range quantitative assay as well as 
numerical integration and global fitting algorithms for data analysis. This combination 
allows for simultaneous analysis of entire progress curves across a broad range of substrate, 
product and inhibitor concentrations. By fitting to kinetic models that explicitly account 
for product inhibition, it is possible to obtain precise determinations of kinetic parameters 
and assign specific modes of inhibition to active compounds.  Furthermore, analysis of 
SENP1 mutants and the effects of ionic strength has generated insight into important 
residues for SENP1 substrate recognition and activity, the crucial role of electrostatic 
interactions, and key differences between SENP1 and its closest paralog SENP2. These 
features can be leveraged in efforts to enhance selectivity of inhibitors during drug 
development. 
2. Materials and Methods  
 
FRET substrate construction, expression, and purification.  SFCypet-SUMO1-SFYpet 
and CyPet-SUMO2-SFYPet were constructed in pET15b plasmids with expression under 
control of the lac promoter. A tobacco etch virus protease cleavage sequence was 
introduced at the C-terminus followed by a 10x-His tag.  Plasmids were obtained from Dr. 
Joshua Plotkin to contain a 5’ untranslated region for high yield E. coli  expression 
determined using experimental observation (Kudla et al., 2009).  Additional mutations to 
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the base CFP and YFP coding sequences were made to generate a FRET-optimized pair 
for improved energy transfer, sensitivity, dynamic range, generating Cypet and Ypet 
(Nguyen and Daugherty, 2005).  Lastly, a final set of mutations were introduced to generate 
a superfolder (SF) version of each fluorescent protein to limit aggregation and misfolding 
(Pédelacq et al., 2006).  In addition, a similar construct harboring SUMO 2 was generated. 
Expression was carried out in Rosetta 2 (DE3) E. coli cells expressing rare tRNAs. Large-
scale production was obtained in a single 20L fermentor run.  Initial lysis and extract 
generation was carried out as described below for the catalytic domains of SENP1 and 
SENP2. Purification involved sequential Ni-chelate chromatography (Ni-NTA), desalting 
(G-50), anion exchange (SourceQ) and size exclusion chromatography (Superdex 200). 
 
SENP1 and SENP2 catalytic domain construction, expression, and purification.  N-
terminal His-tagged SENP1 (AA 418-C) and SENP2 (AA 363-C) catalytic domains were 
constructed in pHT2 plasmids under control of the lac promoter.  Plasmids were grown 
under carbenicillin selection and transformed in to Rosetta 2 (DE3) E. coli cells.  Cells 
were grown at 37 °C until OD600 1.1, upon which the temperature was dropped to 18 °C 
and isopropyl b-D-1-thiogalactopyranoside was added to 0.2 mM final.  Cells were grown 
for another 20 hours.  After pelleting cells, they were re-suspended in resuspension buffer 
(10 mM Tris pH8.0, 500 mM NaCl, 5% glycerol, 2 mM imidazole, 1 mM BME, 0.5 mM 
PMSF, 0.5 µL benzonase) and lysed via French press for three cycles. Cell lysate was 
centrifuged at 40,000 x g for 45 min at 4°C.  Protein was purified from the lysate using Ni-
NTA affinity chromatography and stored in 250 mM NaCl, 50 mM Tris pH 7.5, and 1 mM 
dithiothreitol. 
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Generation of substrate samples with defined cleavage fractions.  Samples of fully 
digested SUMO1 substrate were generated by incubating SUMO1 substrate (21 µM) with 
SENP 1CD (21.5 nM) for 6 hours at room temperature.  Enzyme activity was inactivated 
via addition of N-ethylmaleimide (5 mM) and incubated for 30 minutes. Unreacted NEM 
was quenched with Dithiothreitol (20 mM) for 10 minutes.  A sample of intact substrate 
containing the same components and incubated in parallel was obtained in the same manner 
but by altering the order of addition so that the SENP1 CD was inactivated before mixing 
with the substrate. The reactant and product sources were then mixed in different ratios to 
generate stable samples containing fractions of cleaved substrate of 0, 0.2, 0.4, 0.6, 0.8 and 
1. 
 
Fluorescence spectra.  Samples of both intact and fully digested SUMO1 substrate as well 
as samples with intermediate cleavage fractions of the substrate were prepared as indicated 
above.  Fluorescence spectra were obtained in a HORIBA fluoromax3 fluorimeter at room 
temperature using 2 nm excitation and emission slit widths. Scans were obtained using a 
rectangular microcuvette with 0.1 cm excitation and 1 cm emission pathlengths. No 
correction for primary or secondary inner filter effects was necessary since calculated 
absorbance based on absorption spectra of the samples remained <0.01 across both the 
excitation and emission pathlengths at the wavelengths probed.  Emission scans from 450 
to 650 nm were obtained at 1 nm resolution and 0.1s integration time at excitation 
wavelengths from 300 to 600 nm at 10 nm intervals or at the wavelength indicated in the 
figures. Emission data were corrected for lamp intensity at the specific excitation 
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wavelength in real time.  Data from triplicate scans were averaged and the values from 
corresponding blank samples were subtracted.  Raman as well as first and second order 
Rayleigh scatter signals remaining after blank subtraction were suppressed by applying a 
high band pass filter and smoothing in order to generate the Excitation/emission matrix 
data in Figure 2-1C.   
 
Melting temperature determination. Thermal shift experiments were carried out using a 
Thermofluor 384 ELS system (Johnson & Johnson). Protein unfolding was examined by 
monitoring the fluorescence of ANS (1-anilinonaphthalene-8-sulfonic acid) by increasing 
the temperature from 25° to 60°C. All samples were prepared in quadruplicate. Final 
protein sample concentration was 0.2 mg/mL, and 0.1 mM ANS. To limit evaporation, the 
samples were covered with 1.5 µL of silicon oil. Buffers or salts tested for stability were 
added as a 2X stock to the protein and dye mixture. The reaction mixture was allowed to 
equilibrate for 30 min at room temperature in the dark before beginning the denaturation 
experiments. Melting temperatures were obtained as the inflection points of the 
fluorescence signal as a function of temperature. 
 
In Vitro ratiometric FRET assay. For 96-well assays, reactions were 100 µL final and 
performed in high or low salt buffer solution (20 mM TrisCl pH 8.0, 250 µM Na·EDTA, 
20 mM NaCl or 100 mM NaCl, 10 mM b-Mercaptoethanol, 0.1 mg mL-1 bovine serum 
albumin, 0.01% NP-40). Enzyme concentration ranged from 75-200 pM depending on the 
number of plates and frequency of reads. Substrate concentration was 100 nM.  Time 
delays between addition of enzyme to start reaction for each well and the first read by the 
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instrument were accounted for.  A Spectramax M5 plate reader was used for data capture 
with excitation at 405 nm and emission measured at 475 and 525 nm. To adapt the assay 
to 384 well formats, a scaling to a 20 µL final volume was used and data were acquired in 
an Envision plate reader with CFP and YFP filters. 
 
Kinetic analysis SENP assay.  Assays were carried out in a 96 well format essentially as 
described for the ratiometric assay at concentrations of substrate ranging from 3 nM to 2 
µM in the absence or presence of various concentrations of inhibitor (purified free 
SUMO1) ranging from 7 nM to 200 nM.  The amount of enzyme in each well was adjusted 
based on kinetic modeling (see below) in order to achieve progress curves of comparable 
time trajectories.  This approach allows for monitoring of a wide range of substrate and 
inhibitor combinations over the same time frame and after exposure to the same 
illumination. This permits comparisons without concerns about differential photobleaching 
or other time-dependent effects.  Samples of intact and completely digested substrate 
(obtained by incubation with a large excess of enzyme) at each of the concentrations of 
substrate tested were monitored in parallel.    
 
Data analysis and model fitting.  Data for kinetic characterization obtained as described 
above were processed as follows:  Raw channel 2 data was blank subtracted and corrected 
for non-linearity with respect to concentration by applying a second-degree polynomial 
correction factor derived from analysis of the standard curve data. The correction factor 
values increase with concentration but did not exceed ~15% at the highest substrate 
concentrations used (~4 µM).  Correc
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substrate cleaved (F) assuming that the signal observed is a linear combination of the 
contributions of the substrate and product using the following formula: 
𝐹(𝑡) = 𝐶ℎ( 𝑡) − 𝐶ℎ( 𝑡𝐶ℎ( 𝑡) − 𝐶ℎ((𝑡+) 
with 𝐶ℎ2 𝑡)  and 𝐶ℎ2(𝑡+) corresponding to the fluorescence values of the intact and 
completely digested substrate obtained in parallel at each substrate concentration.  The 
amount of product generated as a function of time at each initial substrate concentration 
was obtained by multiplying 𝐹(𝑡) by the corresponding substrate concentration.  Fitting to 
obtain kinetic parameters was carried out by iterative minimization of the global 
normalized sum of square differences between all observed and predicted values across all 
combinations of conditions. Predicted values were generated at each iteration by numerical 
integration (fourth order Runge-Kutta) of the rate equation for a rapid equilibrium mixed 
type inhibition model with product inhibition (Segel, 1975).  
Equation 1:  
 𝑣 = ./012/	 45678 4 9:565;<7 4567 =5>7[9]5;7 4 9:565;	 
 
Corresponding to the following reaction scheme: 
Scheme 1: 
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where 𝐾B and 𝐾C correspond to substrate and product dissociation constants and 𝑘EFG as the 
catalytic rate constant. This model accommodates mixed types of inhibition. If substrate 
and inhibitor binding is mutually exclusive (competitive mechanism), 𝛼 ≫ 1.  In pure 
noncompetitive inhibition, 𝛽 ≪ 1 and 𝑎~1 whereas in pure uncompetitive inhibition, 𝛽 =0 and 𝑎 ≪ 1. 
Numerical integration and minimization were carried out in Microsoft Excel using a 
custom spreadsheet and the GRG nonlinear solver with forward derivatives and a 
convergence threshold of 10-4.  Standard deviations for the parameters were obtained from 
independent fitting of >250 bootstrapped datasets derived from the experimental data. 
3. Results 
 
FRET Substrate Generation 
The FRET substrate was designed with the pair-optimized Cypet at the N-terminus 
of SUMO with a small peptide linker between the fluorophore and SUMO.  Following the 
SUMO maturation recognition site at the C-terminus is a peptide linker and the other 
member of the FRET pair, Ypet (Figure 2-1A).  Using the superfolder (SF) versions of the 
fluorophores allowed for the production of highly purified protein in substantial quantities 
(data in possession of Dr. Jorge Iniguez) (Figure2-1B, lane 1).  In this set-up, the linkers 
allow the SFCypet-SFYpet pair to be in close proximity for efficient energy transfer while 
allowing access by SENPs to the SUMO Gly-Gly cleavage site to generate the SFCypet-
SUMO1 and the SFYpet products (Figure 2-1B, lane 6).  
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FRET Substrate Spectral Characterization 
Purified SFCypet-SUMO1-SFYpet substrate fluorescent properties were assessed 
to determine the optimal wavelength for excitation as well as the wavelengths for detecting 
SFCypet and SFYpet signal for both intact substrate and cleaved products.  Analysis of 
samples of intact substrate and fully cleaved product species for fluorescent analysis were 
confirmed for their expected pattern of species via SDS-PAGE (Figure 2-1B lanes 1 and 
6).  Fluorescent spectra on intact substrate samples show that excitation of substrate at 405 
nm generates a prominent fluorescence signal at emission wavelengths of 525 nm, the 
signal dominated by SFYpet emissions (Figure 2-1C, left).  The emission signal at 475 nm, 
which pertains to SFCypet, is relatively weak under these conditions. In contrast, excitation 
at ~500 nm directly excites the SFYpet, generating an emission signal at 525 nm and no 
signal at 475 nm.  In the fully cleaved product, similar SFCypet excitation at 405 nm 
generates an emission spectrum with a drastically reduced signal at 525 nm and an 
enhanced signal at 475 nm (Figure 2-1C, right).  By using excitation at 405 nm, the direct 
excitation of SFYpet is limited (lower 525 emission) while still achieving SFCypet 
excitation. The dynamic range in signal between intact substrate and cleaved product is 
much larger for the signal at 525 nm (approximately 10-fold) than 475 nm (Figure 2-1D). 
The remaining 525 nm emission signal in fully cleaved product is a result of minimal direct 
SFCypet excitation. Based on these results, to assess SENP protease activity in our FRET-
based assays an excitation wavelength of 405 nm was used with emission measured at 475 
nm (channel 1) and 525 nm (channel 2).  Protease activity can be monitored via the loss in 
channel 2 signal and concurrent increase in channel 1 signal due to loss of FRET. 
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Figure 2-1 Substrate Characterization. 
A) Depiction of FRET substrate organization showing excitation of SFCypet at 405 nm with 
transfer of the energy in intact substrate to SFYpet, leading to fluorescence emission at 525 
nm.  After protease activity on the substrate by SENP, SFYpet is no longer in proximity to 
SFCypet and emission at 475 nm is increased. B) SDS-PAGE of different ratios of intact FRET 
substrate (75 kDa) and the fully cleaved product (42 kDa and 33 kDa). C) Fluorescence spectra 
of intact substrate (left) and cleaved/mature product (right). D) Fluorescence intensity after 
excitation at 405 nm for the six ratios of cleaved product to intact substrate. 
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Ratiometric Assay Characterization 
With the substrate conditions optimized, the behavior of the assay and its ability to 
measure SENP protease activity in real time was assessed.  As the reaction progresses, the 
channel 2 signal decreases while the channel 1 signal increases, but not linearly due to 
significant product inhibition (Figure 2-2A). The ratiometric change that can be plotted as 
a function of time to assess enzyme activity (Figure 2-2B). As seen in the initial substrate 
characterization, the magnitude of change in channel 2 signal over time is much larger than 
Figure 2-2 FRET assay performance. 
A) Change in channel 1(475 nm) and channel 2 (525 nm) fluorescence signal over time at 
different concentrations of SENP1 enzyme present.  B) Plots of the ratios of channel 1/channel 
2 using the data from (A).  C) The slopes of the ratios over time from panel (B) plotted as a 
function of enzyme concentration.  D) The effects of DMSO on FRET ratios showing that the 
assay is tolerant to high levels of DMSO. 
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the magnitude for channel 1.  The ratiometric readout functions as an index of enzyme 
activity and the slopes of these ratios as a function of enzyme concentration display a linear 
relationship (Figure 2-2C).  In addition to enabling assessment of SENP activity across a 
large range of enzyme concentrations and over a long period of time, the assay is also quite 
tolerant of the presence of DMSO (Figure 2-2D).  The tolerance to DMSO is important for 
use of the assay to test potential small molecule inhibitors, as often these small molecules 
are stored and dissolved in it.  With a goal of discovering small molecule SENP1 inhibitors, 
this DMSO tolerance is essential for a robust assay for future high-throughput screening. 
The ratiometric approach allows for slight variations in substrate concentration to be 
inconsequential.  This allows for adaptation of the assay to miniaturization to 384 and 1536 
well formats to increase the throughput for studying SENPs.  Under the ratiometric 
approach the assay can be utilized in endpoint, dose response, and time course assays to 
characterize inhibitors for intrinsic fluorescence, selectivity to SENP isoforms, and to 
develop structure activity relationships among families of small molecule inhibitors. 
 
SENP enzyme condition optimization in the FRET assay 
The protease activity of the catalytic domains of SENP1 and SENP1’s closest 
paralog, SENP2, were evaluated under different pH and salt conditions.  The salt sensitivity 
of SENP1 relative to SENP2 differ dramatically (Figure 2-3A).  As the concentration of 
salt increases from 20 mM to 100 mM, the maximum catalytic activity of SENP1 decreases 
throughout while SENP2 approaches maximal activity.  Whether NaCl, LiCl, or KCl, the 
SENP salt sensitivity curves behaved the same way (data not shown).  In contrast to the 
differing behaviors between the two enzymes concerning salt, their changes in stability and 
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activity at differing pH values were more congruent. The lack of destabilization of the 
enzymes, suggesting that the effects of ionic strength on SENP activity may reflect effects 
Figure 2-3 SENP condition optimization for FRET assay. 
A) SENP1 and SENP2 activity were monitored via the ratiometric FRET assay under different 
salt conditions.  In addition to NaCl (shown), LiCl and KCl were also tested with similar results 
in salt sensitivity.  B) Thermofluor-determined melting points of SENP1 and SENP2 at 
different pH and salt conditions. C) Using the ratiometric FRET assay, SENP activity 
determined as a function of pH. 
 64 
on substrate interactions more than the intrinsic properties of the SENPs in isolation. Both 
enzymes show the most thermal stability at a pH near 6.5 to 7 and show optimal catalytic 
activity against the FRET substrate at a pH between 8 and 9 (Figure 2-3B and C).  From 
these results, buffer conditions of pH 8 were used for all SENP assays and 20 mM NaCl 
was used for SENP1 while 100 mM was used for SENP2 unless otherwise noted. 
 
Kinetic Characterization of SENP enzymes 
While the ratiometric analysis is a robust tool for screening conditions and potential 
small molecule inhibitors, at low substrate concentrations, the ratio or enzyme rate is 
susceptible to small, noise-related changes in channel 1 signal because of its small dynamic 
range and signal to noise ratio.  Yet low substrate concentrations are needed to obtain 
kinetic constants for SENPs and their SUMO processing.  Because of the high affinity 
interaction between the two and the need to test at concentrations above and below these 
binding constants, we devised a quantitative approach based on the channel 2 signal alone 
instead of the ratio of channel 1 to channel 2.   
Since the goals of this thesis are centered on the discovery and development of 
small molecule inhibitors of SENP1 and much of the binding affinity between SUMO1 and 
SENP1 is driven by interactions with the globular b-grasp domain, significant product 
inhibition is expected and mature free SUMO1 would be expected to behave as a 
competitive inhibitor.  We therefore tested the effects of purified mature free SUMO1 as 
an inhibitor.  Using a matrix of conditions where the concentrations of SENP1 WT catalytic 
domain, SFCypet-SUMO1-SFYpet, and free SUMO1 were varied to maximize the 
coverage of data points at critical points related to substrate and product binding affinities 
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(Figure 2-4A). Channel 2 fluorescent values were converted to product concentration over 
time as described under materials and methods.   
Figure 2-4 Kinetic characterization of SENP1 with free SUMO1 inhibitor. 
A) Representative progress curves for the matrix of substrate and mature free SUMO1 inhibitor 
conditions used to determine SENP1 kinetic constants and the inhibitory constant of mature 
free SUMO1.  Fits obtained are derived from simultaneous global fitting of the model to all 
the progress curves.  B) Representative curve from (A) enlarged to show individual progress 
curve fitting. 
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The results of global fitting revealed in an unbiased manner that mature free 
SUMO1 is a competitive inhibitor as anticipated since when all parameters are allowed to 
float,  minimization yielded a value of  α = 23.1 which under the range of concentrations 
of substrate analyzed would imply essentially mutually exclusive binding between 
substrate and inhibitor.  Further analysis carried out with a purely competitive scheme 
(fixing α to a very large number and β to 0) yielded values for the kinetic parameters kcat, 
Ks, and Kp for SENP1, where Ks is the binding affinity for substrate and Kp is the binding 
affinity for the product and Ki is the affinity for free SUMO1 (Figure 2-5A).  The SENP1 
Ks and Kp values are nearly the same and the Ki value for free SUMO1 is in the same order 
of magnitude.  These values clearly highlight for the first time in a rigorous manner that 
SENP1 is subject to extensive product inhibition. The similar affinities for free SUMO1 
and the Cypet SUMO1 product is not surprising given the lack of binding affinity from the 
C-terminal tail residues near the SUMO processing site based on the crystal structure of 
the complex and the retention of nearly all residues contributing to the binding affinity 
present in the processed or mature forms of substrate.  This also indicates that the 
fluorophores on the FRET substrate are simply serving as a chemical tool to monitor SENP 
activity and have little effect on substrate or product binding. 
With the ability to determine SENP kinetic constants using the channel 2 analysis 
and considering the differential salt sensitivity of SENP1 and SENP2, the two enzymes 
were tested under their alternative salt conditions.  Essentially, SENP1 was tested at 
SENP2’s ideal salt concentration and vice-a-versa.  As seen in Figure 2-5B, the kcat value 
for SENP1 does not change when salt concentration is increased, but its affinity for 
substrate and cleaved product are weakened substantially.  In contrast, for SENP2 at low 
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salt concentration, its kcat is halved and affinity for substrate and product is weakened by 
more than three-fold and more than eight-fold respectively.  Treating substrate affinity as 
an apparent Km, the catalytic efficiency of SENP2 (kcat/Ks) drops from around 40 × 106 M-
1s-1 at high salt to approximately 5.5 × 106 M-1s-1 at low salt.  Similar analysis for SENP1 
Figure 2-5 Kinetic characterization summary. 
Summary tables of determination of kinetic constants for SENP1 WT, SENP1 mutants and 
SENP2 WT in different salt conditions and with different SUMO substrates. The standard 
deviation of the parameters are indicated in parenthesis. 
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shows a change from nearly 108 × 106 M-1s-1 at low salt to 2.7 × 106 M-1s-1 at high salt.  
Elucidation of these kinetic constants further supports the activity-based observations from 
the ratiometric studies with the two enzymes when tested under a spectrum of salt 
concentrations.  
The dramatic influence of ionic strength supports the view that the electrostatics of 
the environment are important in SENP function.  Considering the salt-based results, the 
structures of SENP1 WT and SENP2 WT were compared to identify residues near the 
SUMO binding site that differ between the two in charge.  Two lysine residues in SENP1 
were identified that are a glycine in SENP2 in comparison.  In essentially making single 
residue chimeras within SENP1, a series of lysine to glycine SENP1 mutants were 
generated and tested for kinetic characterization.  Kinetic analysis was performed on the 
catalytic domains of SENP1 WT, SENP2 WT, SENP1 K455G, SENP1 K515G, and the 
double mutant SENP1 K455,515G at their optimized salt conditions (Figure 2-5C).  These 
results show that loss of K455 improves substrate and product binding affinity while 
slowing kcat in comparison to SENP1 WT.  In contrast, the other single lysine mutant, 
K515G, shows a substantially reduced substrate and product binding affinity and enhanced 
kcat while the double lysine mutant’s kinetic constants are in between these two individual 
mutants.  These data suggest that the loss of lysine at the 455 position improves substrate 
and product binding, but the higher affinity binding makes it more difficult for enzyme to 
shed the product at the expense of a loss in kcat.  The loss of substrate affinity in the SENP1 
K515G mutant to a value beyond the affinity that is found with SENP2 suggest that while 
this lysine is important for substrate binding in SENP1, there are other residues in SENP2 
that overcome the effect of the loss of that lysine to maintain better affinity for substrate. 
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Additionally, a SUMO2 version of the FRET substrate was also tested at low and 
high salt for SENP1 WT and SENP2 WT (Figure 2-5D).  For SENP1, protease activity 
against SUMO2 seems to be unaffected by salt with respect to kcat, Ks, and Kp.  In 
comparing SENP1’s kinetic constants at 20 mM salt for SUMO1 versus SUMO2, SUMO1 
has a lower turnover but enhanced substrate affinity and apparent catalytic efficiency 
(kcat/Ks at 77 × 106 M-1s-1).  For SENP2, the kcat is unaffected by salt with SUMO2 
processing, but the affinity for substrate and product and apparent catalytic efficiency are 
reduced at 100 mM salt. Additionally, in comparing SENP2 with SUMO1 versus SUMO2 
processing, at high salt the kcat is improved for SUMO2 while the apparent catalytic 
efficiencies are the same (SUMO1: 40 × 106 M-1s-1, SUMO2: 41 × 106 M-1s-1).  In contrast, 
at low salt, SENP2’s apparent catalytic efficiency for SUMO2 is nearly 60-fold greater 
than for SUMO1.  Previously reported results on SUMO isoform maturation preferences 
for SENP enzymes show that SENP1 shows slight preference for SUMO1 over SUMO2/3 
but robustly processes all SUMO isoforms (Hickey et al., 2012; Kolli et al., 2010; Mendes 
et al., 2016; Mikolajczyk et al., 2007; Shen et al., 2006). In contrast, while SENP2 can also 
process all three SUMO isoforms, it shows a substantial preference for SUMO2/3 over 
SUMO1.  These results show that at low salt, the apparent catalytic efficiencies (kcat/Ks) 
are consistent with the published SENP preferences for SUMO isoform maturation.  In 
contrast, at the higher salt concentrations, which are in closer proximity to physiologically 
relevant salt concentrations, SENP1 shows an apparent preference for SUMO2 and SENP2 
shows no preference for SUMO isoforms.   
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4. Discussion 
 
Development of a robust assay for assessing SENP protease activity is essential for 
the future discovery of inhibitors as well as the characterization and guided further 
derivatization of hits.  In this work, a FRET-optimized substrate capable of high-yield 
purification was generated.  This substrate, SFCypet-SUMO1-SFYpet, is a powerful tool 
for both screening for potential inhibitors and detailed kinetic analysis.  In a high 
throughput screening setting, a ratiometric approach to the analysis allows for the robust 
yet simple survey of large libraries of compounds.  With the small volumes used in 384 
and 1536-well screening formats, the ratiometric approach is able to accommodate 
potential inconsistencies in protein concentration from well to well.  This format also 
allows for higher throughput in testing compounds in a dose-responsive and time course 
dependent manner to determine properties related to inhibitor-target selectivity and 
structure activity relationships.  Additionally, with the initial fluorescence and through 
monitoring their signals over time, this approach allows for detection of compounds 
interfering with substrate fluorescence and potentially giving false positives for inhibition.  
These attributes along with the tolerance to DMSO make the ratiometric FRET assay a 
powerful tool for future exploration of SENP1 inhibitors.  
While the ratiometric approach has tremendous utility, the ratio is not directly 
proportional to the reaction rate.  The limitations of the ratiometric approach arise from a 
low channel 1 dynamic range that limits the minimum concentration of substrate that can 
be assayed, and the compounding fluorescent signals due to continued channel 2 signal 
from direct SFYpet stimulation in both intact substrate and cleaved product.  Using analysis 
specifically based on channel 2 readout allows for detailed determination of kinetic 
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constants of SENP enzymes.  These details breakdown which particular component(s) are 
affected under changing enzyme constructs and/or assay conditions.  Using this approach, 
the observations found in the ratiometric approach on the differential effects of salt on 
enzyme activity can be further understood.  Beyond the changes in activity, the effects of 
salt specifically on substrate binding vs enzyme catalytic activity can be parsed out.  The 
assessment of SENP1 mutants shows the additional utility of the channel 2 approach to 
probe specific residues for their individual roles in substrate binding and catalytic activity.  
The further evidence that mature free SUMO1 functions as an inhibitor in the assay 
supports our hypothesis on the significant product inhibition observed.  Previous reports 
on the development of assays for monitoring SENP activity have failed to account for this 
product inhibition despite its impact.  Additionally, the mature free SUMO1 work shows 
that we can determine the mechanism of inhibition of future identified inhibitors in an 
unbiased manner and the residues responsible for inhibitor binding and selectivity can also 
be potentially probed.  As opposed to the steady-state assumptions and use of initial rate 
estimates to determine kinetic constants, the global fitting of the entire reaction progress 
curves allows for inclusion of the array of data points that sample near critical points for 
determining the constants.  Within the matrix of conditions, each well’s conditions change 
throughout the progress of the reaction, so fitting the entire curve increases the robustness 
of extraction of kinetic constants. 
Within the properties of the assays, the finding that SENP activity is highest when 
the pH is more basic (pH 8-9) is supportive of the mechanism of a cysteine protease.  In 
the Asp-His-Cys triad, the aspartate hydrogen-bonds with or extracts a proton from 
histidine, which then bonds with Cys’ thiol hydrogen to generate a stronger nucleophile at 
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the cysteine for eventual peptide bond hydrolysis.  In basic environments that still preserve 
SENP protein structure, the potential protonation of the nucleophilic thiol by a hydronium 
ion is limited as compared to acidic environments. 
As another item related to the properties and optimization of the assay, the 
differential sensitivity to salt is a unique finding to the SUMO protease field.  Others who 
have used the same catalytic domains to study SENP1 and SENP2 activity have 
unknowingly tested SENP2 at its suboptimal conditions to show the selectivity of any 
substrate or inhibitor for a SENP paralog.  The evidence presented here shows that in 
testing the enzymes under the same conditions, selectivity in substrate or enzyme binding 
may be a product of a number of factors, including natural differences in ideal 
microenvironment at the site of catalysis instead of specifics regarding actual substrate or 
inhibitor binding.  This could lead researchers astray in leveraging perceived structure 
activity relationships to attempt to generate inhibitors more selective for a SENP paralog.  
With the SFCypet-SUMO1-SFYpet as a substrate and the concurrent optimization of assay 
conditions and analysis to cater to different needs (structure activity relationships versus 
kcat for example), we have developed a robust tool amenable to meeting the evolving 
demands of a small molecule inhibitor campaign. 
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Chapter 3  
 
High Throughput Screening for SENP1 inhibitors and characterization 
of identified small molecule hits 
1. Introduction 
 
 Based on the coverage of SUMO-based2 post-translational modifications (PTMs) in 
the proteome, SUMO is considered to be involved in most if not all cellular processes.  
Consistent with this integral role, SUMO has been implicated in numerous diseases, 
including many cancers, diabetes, neurodegenerative diseases, and vascular disease.  
Consequently, the SUMO pathway has become a target of study for potential therapeutics.  
 Though there are notable exceptions, the general consensus of SUMO-driven 
effects on transcription factors and other transcription-modifying factors is that 
SUMOylation decreases their transcriptional output (Chymkowitch et al., 2015).  In the 
context of the highly proliferative disease of cancer, the subdued induction of transcription 
by SUMOylation can be a helpful strategy to modulate production of oncogenes.  The 
development and optimization of protein activators is generally considered more difficult 
                                                
‡ High throughput screening and rank order inhibition with purinergic receptor inhibitors 
were performed by Dr. Jorge Iñiguez-Lluhí and Angelica Willis.  Carrie M. Johnson 
performed the dose-response testing of HTS hits, class 8 characterization, orthogonal 
inhibition with PPNDS and cell extracts, PPNDS characterization, and PPNDS time 
dependence. In collaboration with Dr. Jorge Iñiguez-Lluhí and Melissa Lemke, Carrie M. 
Johnson performed Class 1 characterization. 
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than inhibitors (Darby et al., 2014; Zorn and Wells, 2010).  Instead of trying to activate the 
SUMOylation E1, E2, E3 pathway, efforts targeting the SUMO system have been geared 
towards generating inhibitors for SENP enzymes, as they are responsible for 
deSUMOylating modified proteins.  As a result of this inhibition, levels of SUMOylation 
and the resulting subdued transcriptional activity are maintained.   
A number of groups have targeted the SENP enzymes for inhibition.  Initial work 
in the study of SENPs used a SUMO construct containing an electrophilic trap of a vinyl 
sulfone off its C-terminal glycine.  This construct formed covalent adducts to the thiol 
group of the catalytic cysteine in SENP enzymes to inhibit their protease activity (Hemelaar 
et al., 2004).  Using the C-terminal tail residues of SUMO as a guide, others have used 
short peptidyl chains with vinyl sulfones (Borodovsky et al., 2005).  Because the vinyl 
sulfone is a highly reactive Michael acceptor, these inhibitors are nonspecific and capable 
of inhibiting the SUMOylation E1 and E2 machinery along with other potential reactive 
cysteines.  Following this lead, a short SENP specific peptide inhibitor equipped with a 
different electrophilic trap, a fluoromethylketone, was used to inhibit SENP1 and SENP2 
(Dobrotă et al., 2012). This functional group is smaller and better mimics the glycine-like 
size limitations imposed by the tryptophan tunnel covering the catalytic cysteine. Though 
selective for SENP2 over SENP1, this probe still had high levels of background labeling 
and formed covalent adducts with SENP6, SENP7, and other species in the cellular milieu.  
Aside from peptides, small molecules and peptidomimetic inhibitors have been 
developed to inhibit SUMO proteases. Starting with the hits from a screen of a library of 
known cysteine protease inhibitors, analogs have been synthesized to generate inhibitors 
with micromolar-potency for SENP1 and its closest related homolog, SENP2, with 
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increasing specificity and improving pharmacokinetic properties. Some of these inhibitors 
were equipped with reactive aza-epoxide or acyloxymethyketone (AOMK) groups 
(Albrow et al., 2011).  Acting as a Michael acceptor, the AOMK warhead is glycine-like 
in size and able to enter the SENP tryptophan tunnel.  These AOMK-based inhibitors were 
shown to selectively form covalent adducts with SENP enzymes, even when added to 
complex protein mixtures.  Deviations away from the peptide backbone with enhanced 
hydrophobicity have been employed to enhance the selectivity and stability of inhibitors. 
Qiao et al. added a benzodiazepine functionality with an aldehyde off the central ring to a 
short peptidomimetic linker to create a family of compounds with better pharmacokinetic 
properties.  These inhibitors showed low micromolar IC50 values against SENP1 in purified 
protein assays and notably inhibited cancer cell growth in vitro at similar micromolar 
concentrations (Qiao et al., 2011).  Using a synthesized library of phenylurea derivatives 
known to inhibit HIF1a, Uno et al achieved selectivity for SENP1. Using an in vitro 
fluorogenic SUMO1-AMC (7-amino-4-methylcoumarin) assay they were able to achieve 
IC50 values as low as 29.6 µM for SENP1 while SENP2 showed no significant inhibition 
up to 100 µM (Uno et al., 2012).  
Taking advantage of growth in computational modeling and dynamics, virtual 
screening for SENP inhibitors has also been employed.  By using known crystal structures 
of SENP1 in complex with SUMO, labs have been able to efficiently screen hundreds of 
thousands of compounds and then assay top hits in biological assays to confirm the in silico 
findings.  Using the Glide program and then docking the confirmed hits to understand their 
binding mode near the SENP active site, Chen et al. used rational drug design to attempt 
to further enhance the potency of potential inhibitors. Their inhibitors were tested for 
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SENP1 inhibition using a gel-based isopeptidase assay with RanGAP-SUMO2 substrates 
and showed IC50 values ranging as low as 1 to 2 µM (Chen et al., 2012).  Among other 
virtual screening efforts targeting SENP1, new chemotypes for inhibitors have arisen, 
including noncovalent and non-competitive inhibitors (Kumar et al., 2014; Madu et al., 
2013; Wen et al., 2014; Zhao et al., 2016).  While various assays were used to validate 
these hits, including NMR, gel-based, and the SUMO-CHOP reporter assay, none showed 
specificity to SENP1 over SENP2 when tested and only one showed cell permeability.  
Recently, Wu et al. identified the natural product Momordin Ic as a SENP1 
inhibitor.  In addition to showing in vitro activity against SENP1 in purified proteins and 
mammalian cancer cell culture, they went beyond previous SENP1 inhibitor exploration to 
demonstrate inhibitory activity in vivo.  Using a tumor xenograft model of PC3 cells in 
Balb/c nude mice, intraperitoneal injection of Momordin Ic slowed tumor growth both by 
PCNA staining and tumor volume (Wu et al., 2016).  The tumor cells treated with 
Momordin Ic also showed increased apoptosis via terminal deoxynucleotide transferase 
dUTP nick-end labeling (TUNEL) staining and increased levels of SUMO1 and SUMO2/3 
staining indicating accumulating SUMO-conjugates. Using a gel-based assay with 
RanGAP1-SUMO2 substrate, the IC50 was 15.4 µM but mechanism of inhibition was not 
determined. 
Of all the designed SENP1 inhibitors thus far, the rationale behind the drug design 
was focused on targeting the active site cysteine tunnel.  With either peptidomimetics using 
the SUMO C-terminal tail as inspiration, electrophilic warheads selective for cysteine 
proteases, or virtual screening focused on the active site, very little if any weight is given 
to the larger surface of interaction between the globular b-grasp domain of SUMO and the 
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SENP catalytic domain.  This region of substantial protein-protein interaction drives much 
of the activation of SENP enzymes through long-range allostery and is considered to be 
another potential area to target in generating SENP inhibitors (Chen et al., 2014; Kumar 
and Zhang, 2013; Shi et al., 2013). 
Using the ratiometric FRET-based assay described in the second chapter, our group 
engaged in a high throughput screening (HTS) campaign to identify and characterize 
SENP1 inhibitors.  At the outset, it is important to note that the primary screening described 
below was initiated prior to the start of my dissertation work and multiple individuals 
contributed to the data in Figure 3-1.  This data and corresponding experimental details are 
included here for the sake of completeness and clarity.  Because the full SUMO1 protein 
is present in the FRET substrate, the assay we developed is capable of detecting potential 
small molecule inhibitors that function by disruption of SUMO binding at its C-terminal 
tail or b-grasp domain. The screening assay demonstrated appropriate performance needed 
for a quality HTS, including tolerance to DMSO, good reproducibility, low cost, and a 
robust Z’ factor (Zhang et al., 1999). Kinetic time course and dose-responsive monitoring 
allows for detection of non-specific, interfering compounds. Additional measures were 
taken to prevent redox cycling and generation of reactive oxygen species that could 
generate false positives by using b-mercaptoethanol instead of dithiothreitol (DTT) and the 
addition of catalase to the reaction buffer (Johnston, 2011). Following careful confirmation 
of molecular hits obtained in HTS, commercial derivatives of the parent compound were 
characterized for their inhibitory properties towards the catalytic domain of SENP1 as well 
as the full-length enzyme. The mechanism of action of exemplars of active scaffolds were 
characterized for their mechanism of action and the basis for their selectivity towards 
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SENP1 catalytic domain (CD) versus SENP2 CD was explored through the analysis of 
specific mutants.  
2. Materials and Methods  
 
High throughput screening. The screening campaign at the University of Michigan 
Center for Chemical Genomics involved a primary screen endpoint assay in 384 well 
format (20 µL total volume). Compounds (20-50 µM final concentration) were distributed 
to assay plates via a pin tool and pre-incubated with SENP1 catalytic domain for 10 
minutes. Assays were initiated by addition of SUMO1 FRET substrate and incubated for 
30 minutes at room temperature before reading in an Envision plate reader with CFP and 
YFP filter sets. The positive control for inhibition was absence of enzyme and negative 
control was DMSO vehicle control. Hits from the primary screen were then re-tested in 
triplicate in a time course manner to test for spectral interference and reproducibility.  
Confirmed compounds were then tested in an 8 point (4-150 µM) dose-response in 
duplicates. Compounds devoid of significant interference and displaying Hill coefficients 
near unity were ranked by potency.  This set was assessed against the CCG database of 
HTS results from other screens as well as for Pan Assay Inhibitor (PAINS) chemical 
properties for detection of promiscuous inhibitors. The compounds were then grouped by 
structural similarity and in consultation with our Medicinal Chemistry collaborator, Dr. 
Scott Larsen, the most promising classes based on physicochemical properties and 
synthetic tractability were pursued further. Commercially available compounds and 
selected analogs were repurchased for end point and dose response testing from fresh 
powders. 
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The screening campaign of the NIH molecular Libraries Program collection was 
carried out at the Sanford-Burnham as part of the NIH MLPCN initiative.  The primary 
screening was done via an endpoint assay in a 1536 well format at a volume of 6.03 µL  
using the in vitro FRET assay buffer conditions described above with 333.3 U/mL catalase 
added. In each well, 10 µM of respective compound incubated with 20 pM SENP1 CD 
enzyme and the reactions were initiated by addition of substrate at a final concentration of 
25 nM and incubated for 50 min.  Plates were read on a PerkinElmer Envision Plate reader 
equipped with CFP and YFP filters. Positive control for inhibition was absence of enzyme 
and negative control was compound DMSO vehicle control.  Active compounds were re-
tested in quadruplicate in a time course and endpoint assay.  Confirmed hits from the 
primary screen were subjected to cheminformatics filtering to remove promiscuous 
inhibitors in other screens, overtly reactive compounds and those displaying PAINS 
properties.  The resulting set was assayed in a dose-response format in both a time course 
and endpoint format.  Compounds displaying significant potency were then subjected to a 
confirmatory order of addition test in which compounds were added after completion of 
the reaction to rule out spurious artifactual effects. 
 
In Vitro FRET assay for confirmation and characterization. Reactions were 100 µL 
final and performed in high or low salt buffer solution (20 mM TrisCl pH 8.0, 250 µM 
Na·EDTA, 20 mM NaCl or 100 mM NaCl, 10 mM b-Mercaptoethanol, 0.1 mg mL-1 bovine 
serum albumin, 0.01% NP-40). Reactions were initiated by the addition of substrate and 
fluorescence was read every minute on a Spectramax M5 plate reader excitation at 405 nm 
and emission measured at 475 and 525 nm. 
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USP2 CD construction, expression, and purification.  USP2 (AA 259-605) was 
subcloned into pET24a vector (Novagen). Rosetta2 (DE3) cells were grown under 
kanamycin selection in TB medium at 37 °C until OD600 1.2. Temperature was decreased 
to 18 °C and isopropyl b-D-1-thiogalactopyranoside was added to 0.2 mM final. Cells were 
grown for another 20 hours. Harvested cells were resuspended in extraction buffer 
containing 10 mM Tris pH8.0, 500 mM NaCl, 5% glycerol, 2 mM imidazole, 1 mM BME, 
0.5 mM PMSF, 0.5 µL benzonase. Cells were lysed by 3 cycles of French press and 
clarified by centrifugation at 40,000 × g 40 min at 4°C. 1.5 mL of Ni-NTA agarose were 
incubated with the clarified supernatant for 1 hour at 4°C rotating. Proteins were eluted by 
the extraction buffer supplemented with 200 mM imidazole. Pooled fractions were gel-
filtered in 50 mM HEPES pH8.0, 150 mM NaCl, 10% glycerol, 0.5 mM Na·EDTA, 1 mM 
DTT. 
 
PPNDS reversibility. 500 nM SENP1 CD was incubated with 10 µM PPNDS or DMSO 
vehicle control for 30 minutes at room temperature in reaction buffer (20 mM TrisCl pH 
8.0, 250 µM Na·EDTA, 20 mM NaCl, 10 mM b-Mercaptoethanol, 0.1 mg mL-1 bovine 
serum albumin, 0.01% NP-40),. The mixture was then diluted 100-fold and served as the 
SENP1 enzyme source for the assay, where it made up 10% of the 100 µL final assay 
volume for an experimental activity concentration of 500 pM. In addition to the enzyme, 
the final assay solution contained reaction buffer, 600 nM SFCypet-SUMO1-SFYpet 
substrate, and 10 µM PPNDS or DMSO vehicle control. Reactions were initiated by the 
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addition of substrate and fluorescence was read every minute on a Spectramax M5 plate 
reader excitation at 405 nm and emission measured at 475 and 525 nm. 
 
Transfection and preparation of cell extracts. HEK293T cells were grown in DMEM 
+10% FBS to 70% confluency and seeded in to 10 cm plates at 3 × 106 cells per plate.  
Cells were incubated overnight. The next morning, the media was exchanged for serum 
free DMEM and cells were transfected using Lipofectamine 2000 and 5 µg DNA per plate. 
A pcDNA3 HA SUMO1 plasmid was used for substrate transfection, pCMV6 SENP1 418-
C was used for enzyme, and empty pCMV6 for a vector control.  After incubating with 
transfection material for six hours, the media was exchanged for fresh DMEM + 10% FBS 
and the cells were incubated for 48 hours. Cells were then harvested on ice with lysis buffer 
(400 mM NaCl, 20 mM HEPES pH 7.4, 5 mM Na·EDTA, 1 mM EGTA, and 1% NP-40).  
For the vector control and SENP1 extracts the lysis buffer was supplemented with 10 mM 
DTT.  For the extracts serving as substrate source and transfected with HA SUMO1, the 
lysis buffer was supplemented with 20 mM NEM to alkylate endogenous SUMO proteases 
and preserve natural SUMOylated substrates.  After incubation of the extracts in the NEM 
supplemented buffer, excess DTT was added to quench any remaining NEM. 
 
Cell extract assay. Total protein concentration of each extract type was determined by 
Bradford assay. Substrate extracts were mixed with equal total protein content from SENP1 
extracts or vector extracts and incubated at room temperature for 15 minutes in a Tris 
reaction buffer (10 mM TrisCl pH 8.0, 500 µM Na·EDTA, 10 mM b-Mercaptoethanol, 
5mM DTT).  In the presence of inhibitor, these mixtures were supplemented with 50 µM 
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PPNDS or equal volume DMSO as a vehicle control.  Reactions were quenched with equal 
volumes of hot 4X SDS sample buffer. Samples were loaded and separated in a 10% SDS-
PAGE gel and either stained for analysis or transferred to a nitrocellulose membrane for 
immunoblot analysis. 
 
Western Blot. Membrane was blocked overnight at 4 °C in 5% nonfat dry milk in Tris-
buffered saline with Tween (TBST: 10 mM Tris pH 7.5, 150 mM NaCl, 0.1% Tween-20). 
The membrane was then rinsed with TBST and a 1:500 solution of mouse anti-HA11 
ascites antibody in TBST was applied to the membrane for one hour at 4 °C.  The 
membrane was again rinsed in TBST and a 1:500 solution of goat anti-mouse horseradish 
peroxidase-conjugated antibody was applied to the membrane for one hour at 4 °C.  The 
membrane was rinsed and imaged using a Li-Cor Odyssey Fc imaging system and 
enhanced chemiluminescent substrate (Thermo Fisher Scientific SuperSignal West Femto 
Maximum Sensitivity Substrate).  Image was quantified using Image Studio software.  
 
Time dependence and Schiff base reduction by NaBH4. In a 10 µL volume, 150 nM 
SENP1 418-C was incubated at room temperature with 40 µM PPNDS for 1 hour in a 
HEPES incubation buffer (20 mM HEPES pH 8.0, 20 mM NaCl, 500 µM Na·EDTA, 0.1 
mM TCEP and 0.01% NP-40).  Following this incubation, 5 µL of fresh 1 M NaBH4 was 
added and allowed to incubate for 1 hour.  This mixture was diluted 100-fold and 
functioned as the enzyme source and was diluted 10-fold in to the assay final.  Specific 
activity of each sample was assessed via serial dilutions of the mixture with Cypet-
SUMO1-YPet substrate in the FRET assay described above. 
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3. Results  
 
HTS and identification of SENP1 inhibitors 
As indicated above, the screening data in this sub-section is the result of a large 
effort and is included here for clarity and completeness. Using chemical libraries available 
at the Center for Chemical Genomics (CCG) at the University of Michigan and at the 
National Institutes of Health Molecular Libraries Probe Production Centers Network, over 
500,000 compounds were screened in total. The overall progressive reduction in candidate 
compounds after each experimental step of the two campaigns are summarized in Figure 
3-1.  The primary screening was done in an end point assay to identify inhibitors of SENP1 
endopeptidase activity against the SFCypet-SUMO1-SFYpet FRET-based construct 
described in Chapter 2. Average plate Z’ scores for the HTS assay were routinely 0.9 or 
greater, signifying a robust screening assay with a broad detection range between positive 
and negative controls (Zhang et al., 1999).  With the advantage of such a robust assay and 
confidence in its performance, a more generous cutoff of compounds showing inhibitory 
activity were categorized as hits in the primary screen for further analysis. Notably, 
although the MLPCN primary screening campaign yielded promising candidates, none 
were proven to be true positives. Active compounds were then subjected to a confirmatory 
order of addition test in which compounds were added after completion of the reaction (All 
compounds should be negative). Unfortunately, none of the compounds passed this test 
since all compounds displayed apparent activity, suggesting that they represented false 
positives and were not pursued further. The reason for the compounds passing previous 
tests of interference is unclear. The lower substrate concentration and smaller assay volume 
utilized in the 1536 well format may have been contributing factors.  Of note, none of the 
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active compounds identified in the CCG collection (see below) were present in the MLPCN 
NIH collection.  
The primary screening of 156,667 compounds at the CCG yielded 2,671 hit 
compounds, which were further analyzed in triplicate for inhibitory activity in a time 
course manner to eliminate compounds that cause aggregation, interfere with the 
fluorescence readout, or possess other non-specific inhibitory activity (Figure 3-1A).  
Figure 3-1 Summary of high throughput screening results. 
The narrowing of hit compounds based on confirmation studies described in each table for the 
high-throughput screens performed at the Center for Chemical Genomics (A) and the National 
Institutes of Health Molecular Libraries Probe Production Center Network (B). 
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Confirmed compounds were then tested in a dose-responsive manner to assess for attractive 
potency and Hill coefficients.  This narrowed the candidate compounds to 117.  These 
compounds were then assessed against the CCG database of HTS results and pan-assay 
interference (PAINS) compounds to discard promiscuous inhibitors (Baell and Holloway, 
2010).  Hits were also tested for specificity to only the SUMO system by testing against 
Figure 3-2 A sampling of HTS hits against SENP1. 
Structural depiction and dose-response curves of a representative molecule from four classes 
of compounds showing inhibitory activity against SENP1.  Total enzyme activity in the 
presence of inhibitor is plotted as a percentage of activity normalized to the activity of SENP1 
in the presence of DMSO vehicle control. 
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the ubiquitin protease USP2 and a ubiquitin FRET substrate with the same fluorophores as 
the SUMO substrate. Commercially available compounds of remaining hits were 
repurchased for both end point and dose response testing of fresh compound.  The list of 
compound hits was narrowed to 34 and they were structurally grouped into 12 classes of 
compounds. These remaining compounds were assessed for synthetic chemical tractability 
and availability of commercial analogs. Four of the classes that were identified for their 
potency, commercially available analogs, and/or synthetic tractability are depicted in 
Figure 3-2.  PPNDS, a pyridoxal phosphate derivative (Class 1), was the most potent with 
sub-micromolar potency against SENP1 activity in the FRET assay. The hit in Class 2 
corresponds to Suramin, a member of the Azo dye class of compounds. Class 8 and class 
10 compounds were identified as classes to pursue initially for further analysis due to their 
more drug-like characteristics compared to the highly charged class 1 and class 2 
compounds. 
Characterization of Group 8 and 10 Compounds 
 Class 8 compounds were determined to be synthetically tractable for future 
synthetic structural derivatization and had numerous commercially available analogs. 
Testing a significant number of these commercial analogs suggested a series of structure 
activity relationships regarding ring sizes and electrochemistry across the pharmacophore 
scaffold (Figure 3-3A). Many of the substitutions that made the molecule more 
hydrophobic also enhanced the measured potency of inhibition against SENP1, including 
increasing size of the A ring and introducing methyl substitutions off the linker region and 
C ring.  
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Figure 3-3 Class 8 Characterization. 
A) Structure Activity Relationships (SAR) of class 8 compounds. The atom or region colored 
in red is the part that is changed as described in the quantitative information below each 
structure. Rings are labeled to ease description of structure activity relationships and activity 
is presented as the log IC50 (M) values of the compound from a dose-responsive assay using 
the FRET SFCypet-SUMO1-SFYpet substrate.  B) Dose-response curve for the purchased 
commercial CCG-172423 compound (blue) and the same compound synthesized in the lab of 
Dr. Scott Larsen (red). Total enzyme activity in the presence of compound is plotted as a 
percentage of activity normalized to the activity of SENP1 in the presence of DMSO vehicle 
control.   C) H1 NMR spectra of CCG-172423.  The spectrum on the left is of the synthesized 
version from Dr. Scott Larsen’s lab and on the right is the purchased commercial version 
(Performed by Jeffrey Zwicker). 
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 In an effort to leverage the SAR obtained on class 8 compounds, Jeffrey Zwicker, 
a medicinal chemist in the group of our collaborator, Dr. Scott Larsen, independently 
developed a synthetic route for synthesizing the most promising candidate from the series 
(CCG-172423). Unfortunately, this preparation was devoid of any inhibitory activity 
against SENP1 (Figure 3-3B). Further chemical analysis was performed and carbon and 
proton NMR spectra for the commercial and independently synthesized preparation yielded 
identical results (Figure 3-3C). Notably, composition analysis of the commercial material 
indicated that despite identical organic spectra to the resynthesized sample, the percentage 
of carbon, oxygen, and nitrogen by weight were below the predicted values (data not 
shown). This suggests that inorganic impurities present in the commercial preparation may 
be responsible for the inhibitory activity detected.  Unfortunately, a similar effort with class 
10 compounds yielded the same negative results. 
 
Class 1 and 2 characterization 
 Following the failure to confirm the activity of the class 8 and 10 compounds, 
attention was turned to classes 1 and 2. Notably, both PPNDS (Class1) and Suramin (Class 
2) are known inhibitors of purinergic receptors, specifically P2X1 (Coddou et al., 2011a). 
Using that knowledge, additional known Suramin-like P2X1 receptor inhibitors were 
assessed for inhibitory activity against SENP1 (Figure 3-4). Despite a lack of functional or 
structural similarity between SENP1 and P2X1, these class 2 compounds displayed similar 
rank orders of potency (based on P2X1 published data) albeit with lower overall potency 
towards SENP1 than P2X1.  
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 Further characterization of the original class 1 hit, PPNDS revealed a notable 
selectivity for SENP1 over SENP2 (approximately 20-fold greater potency) when SENP2 
was assayed at its optimal salt concentration of 100 mM (Figure 3-5B). When PPNDS 
inhibition of SENP2 was assayed in the same conditions as SENP1 (20 mM NaCl), no 
inhibition was observed. Considering the selectivity and potency of PPNDS as a compound 
from the primary screening library, additional commercially available PPNDS-like 
compounds were assayed for potential improved potency and potential structure activity 
relationships (Figure 3-5A). All four compounds contain the pyridoxal phosphate moiety 
Figure 3-4 Rank order inhibition. 
Plot of the -log IC50 (pIC50) (M) values for the indicated P2X1 receptor inhibitors in class 2 
towards P2X1 (derived from literature) and towards SENP1 in the ratiometric FRET-based 
assay. 
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linked to different aromatics appended with charged sulfate groups. PPNDS remained the 
most potent compound but all four were still more potent than the compounds in the other 
Figure 3-5 Class 1 characterization. 
A) Structure activity relationships of commercially available PPNDS-like compounds. IC50 
values determined via a dose-response assay using the SFCypet-SUMO1-SFYpet FRET 
substrate and SENP1 catalytic domain (CD).  B) Dose-response curve of PPNDS inhibition of 
SENP1 CD activity vs SENP2 CD activity in the FRET assay. C) To test for reversibility, a 
plot of SENP1 CD activity after pre-incubation with PPNDS or DMSO vehicle followed by 
dilution and re-assay in the presence of PPNDS or DMSO. D) Lineweaver-Burke plot of the 
inverse of substrate concentration vs the inverse of SENP1 CD velocity at different 
concentrations of PPNDS. 
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classes of identified hits.  Although the significant absorbance of PPNDS precluded a full 
kinetic characterization, reversibility tests and Lineweaver-Burke analysis of initial rates 
over a modest substrate concentration range suggests that PPNDS acts as a reversible 
competitive inhibitor (Figure 3-5C and 5D).  
To confirm that the inhibitory activity of PPNDS is not a peculiarity of the FRET 
based assay, an orthogonal assay using cell extracts was employed. As opposed to testing 
for endopeptidase activity of SENP1 via the FRET-SUMO1 substrate, isopeptidase activity 
against native substrates could be tested with the cell extracts. Using extracts from cells 
transfected to overexpress SENP1 or its empty vector as the enzyme source, inhibition of 
activity by PPNDS (CCG-205018) was tested against extracts of cells transfected with 
hemagglutinin-tagged SUMO1. Over the course of 15 minutes, the changes in signal from 
high molecular weight SUMO-conjugated substrates can be observed. In the presence of 
SENP1 extracts, a substantial loss in high molecular weight HA-SUMO adducts as a 
percentage of total SUMO signal is seen (Figure 3-6A-B: lane 1, 93% vs lane 2, 12%). 
Compared to loss in signal in these lanes and the lack of loss in the lanes where vector 
extract was added, PPNDS inhibited SUMO deconjugation of the natural substrates, as 
HMW SUMO-conjugates still make up 77% of the total SUMO signal (Figure 3-6A and 
B: lane 4).  
Based on the observed selectivity and mechanism of inhibition evidence, a 
structural comparison between SENP1 and SENP2 was performed using the published 
crystal structures of each in complex with SUMO1. Because our work suggests PPNDS 
was a competitive inhibitor, residues near the SUMO binding site were analyzed. 
Deviations in protein residue sterics or electronics between the SENP1 and SENP2 
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catalytic domains were selected as potential target residues for mutagenesis to probe for 
those responsible for the selectivity in inhibition. Two lysine resides found near the SUMO 
Figure 3-6 Class 1 characterization. 
Western blot of cell extracts blotted for hemagglutinin (HA).  Every lane contained HA-
SUMO1 cell extracts to serve as substrate source for cell extracts transfected to overexpress 
full length SENP1 or its empty plasmid vector.  In addition, each lane also contained 50 µM 
compound (CCG-205018=PPNDS) or DMSO vehicle control. CCG-1724253 is an inactive 
compound used as a control.  Samples were incubated for 15 minutes after addition of enzyme 
to substrate extract, and halted via addition of hot SDS sample buffer and boiling of sample.  
B) Quantification of ratio of HA-signal at high molecular weight (HMW) to total HA signal.  
The HMW HA signifies SUMOylated substrates, while the total HA signal would include the 
low molecular weight free SUMO that is released after SENP1 activity. Quantification plot is 
superimposed below each respective lane described in the western blot. 
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binding site in SENP1 are absent in SENP2. These two SENP1 residues, K455 and K515 
were mutated to the SENP2 equivalent glycine residues both in isolation and in 
Figure 3-7 Characterization of PPNDS mediated inhibition. 
A) Representative dose-response curve of PPNDS-mediated inhibition of activity of SENP1 
CD and SENP1 mutants, and SENP2 CD.  Activity was normalized to SENP1 CD activity in 
the presence of DMSO vehicle control.  B) Crystal structure complex (2IY1) of SENP1 CD 
(blue) and SUMO1 (orange ribbon) with the location of SENP1 mutants indicated in yellow 
and the general region of the active cysteine pointed out for reference.  C) Table of kinetic 
parameters of SENP1 CD, SENP1 mutants, and SENP2 CD.  Parameters kcat, Ks and Kp were 
obtained by global fitting. The IC50 values were determined from dose response assays shown 
in A.  Using the Cheng-Prusoff equation (D) and the IC50 values for the respective SENP, the 
inhibitory constant, Ki, was estimated.  E) Plot of the estimated Ki values for each SENP as 
determined by the Cheng-Prusoff equation. 
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combination (Figure 3-7B). Each single lysine mutant had an IC50 value intermediate to 
the PPNDS IC50 value of WT SENP1 and WT SENP2 whereas the double lysine mutant, 
SENP1 K455,515G, had an IC50 value that paralleled that of WT SENP2 (Figure 3-7A). In 
essence, it appeared that as SENP1 became more SENP2-like with just mutation of the 
lysine residues near the SUMO binding site, the potency of PPNDS inhibition became on 
par with SENP2. These results would suggest that the two lysine residues, K455 and K515, 
are key factors in PPNDS-mediated inhibition. Using the data from the detailed kinetic 
analysis of the different enzymes (Figure 3-7C), the Cheng-Prusoff equation (Figure 3-7D) 
was employed to estimate the inhibitory constant. The resulting estimated inhibitory 
constant, Ki, for each enzyme is found in the table in Figure 3-7C and plotted in Figure 3-
7E. These results show that while K455 may contribute to PPNDS-mediated inhibition, 
K515 seems to play a more significant role, with a binding constant for PPNDS slightly 
weaker than SENP2 WT. 
Throughout PPNDS-based experiments, the potency of inhibitory activity appeared 
to drift despite using the same stocks of assay components.  This generated an investigation 
into a possible time-dependence of PPNDS-mediated inhibition with respect to the length 
of time PPNDS was incubated with the enzyme before addition of substrate to begin kinetic 
assay measurements. In carefully monitoring the time between the initial mixing of PPNDS 
and SENP1 and the addition of the FRET-SUMO1 substrate, a time-dependent increase in 
potency was observed (Figure 3-8A). A similar time-dependence was observed in the 
mutants and SENP2, albeit at different magnitudes of effect (Figure 3-8B). As a result of 
this observation of time-dependence and the nature of the chemistry of pyridoxal phosphate 
moieties, the possibility of the formation of a Schiff base between SENP surface lysines 
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residues was hypothesized as a potential explanation for the effect. The electrophilic 
carbonyl carbon of the aldehyde group within pyridoxal phosphate is attacked by the free 
Figure 3-8 PPNDS time dependence. 
A) Representative dose-response curves of PPNDS inhibition of SENP1 CD at different times 
of pre-incubation of SENP1 and PPNDS before addition of substrate to begin the reaction.  To 
the right is a plot of the cumulative and averaged log IC50 values plotted with respect to the 
time of pre-incubation. B) Plot of pre-incubation time versus IC50 values for different SENP1 
CD mutants and SENP2 CD. C) Following incubation with PPNDS or DMSO vehicle control 
for 1 hour, samples were incubated in NaBH4 or water vehicle for one hour and diluted 100-
fold and subsequently assayed for specific activity. Data was normalized to the activity of the 
corresponding unreduced samples.  To the right is a depiction of the hypothesized chemistry 
taking place with Schiff-base formation between the PPNDS aldehyde and SENP1 CD lysines 
with reduction of the reversible reaction via NaBH4. 
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lone pair of electrons in the protein lysine residue, releasing water and forming a reversible 
covalent adduct to the enzyme. This bond can be reduced by sodium borohydride to lose 
the reversibility of the adduct formation and generate a permanent covalent PPNDS-SENP 
Figure 3-9 Representatives of published small molecule SENP inhibitors. 
The published structures of identified SENP inhibitors with the corresponding reference.  
When applicable, the most potent analog of the class of compounds tested is shown.  
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adduct. While the data is not definitive, the SENP1 specific activity following incubation 
with PPNDS and reduction with NaBH4 is severely reduced compared to the untreated 
control (Figure 3-8C column 1 vs column 3).  
4. Discussion  
 
 Within the existing published inhibitors for SENP1 and other SENP enzymes, 
(representatives shown in Figure 3-9), limitations exist with regard to their lack of 
selectivity, unknown or non-ideal mechanisms of inhibition, and/or lack of robust 
validation of inhibition of SENPs through orthogonal experiments.  Despite the difficulties 
in generating potent, selective, reliable inhibitors for SENP1, it remains an attractive 
therapeutic target due its role in numerous disease.  In this work, high throughput screening 
(HTS) with a robust FRET-based assay was employed to discover inhibitors of SENP1 
activity.  Through numerous steps of refining and triaging the list of potential inhibitors 
via end-point, kinetic, and dose-response assays, a few classes of compounds were 
identified for further study. In characterizing compounds for their mechanism of inhibition, 
their selectivity, and a structural understanding of SENP1-inhibitor interactions, important 
residues for inhibitor binding and unique pharmacological parallels to unrelated proteins 
were identified.  
 The robustness of the ratiometric FRET-based assay was a powerful tool to screen 
through hundreds of thousands of compounds for not just the initial primary screen, but 
also in the follow-up work to validate lead compounds and characterize their behavior.  
Using the assay in a dose response set-up allowed for fast assessment of both the selectivity 
of compounds for inhibition of SENP1 versus SENP2 and structure activity relationships 
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among derivatives within compound classes.  The ratiometric FRET-based assay allowed 
for characterization of PPNDS as a competitive, reversible inhibitor that depends on lysine 
515 for selective inhibition of SENP1.  Importantly, the reliability of the robust assay 
allowed for observation of the time-dependent changes in PPNDS potency.  Had the assay 
not been reproducible, the drifting in PPNDS potency may have been attributed to 
alternative confounding variables and not have been noticed.  PPNDS chemistry and the 
time dependence further supported generation of the series of SENP1 lysine mutants to test 
for potential Schiff base formation.  Though not fully conclusive, the data support the 
Schiff base hypothesis, with some recovery of SENP1 activity observed without addition 
of the NaBH4 reducing agent.  The magnitude of change in potency in the time dependence 
plots in IC50 values for different SENP1 mutants (Figure 3-5B) further supports the Cheng-
Prusoff estimated inhibitory constants.  The magnitude of the potency change is reduced 
in SENP1 K515G compared to SENP1 K455G, which might be expected if K515 is the 
target lysine important for Schiff base formation.  Due to the lack of full recovery of 
activity in non-reduced but PPNDS incubated SENP1 and the continued observance of time 
dependence, it is likely that PPNDS binds tightly regardless of Schiff base formation but 
the formation further enhances the potency.  Additionally, it is possible that additional or 
alternative chemistry is taking place that is responsible for the time-dependent inhibition. 
 Our orthogonal tests with PPNDS using cells extracts and a non-FRET-based 
approach support our HTS efforts and validation of PPNDS as a SENP1 inhibitor.  As an 
additional advantage, this assay also tests for isopeptidase activity instead of the 
endopeptidase activity assessed in the single polypeptide SUMO1 substrate used in the 
FRET-based assays.  While the chemistry is similar in both activities in that hydrolysis of 
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a peptide bond is occurring, the difference in rotational degrees of freedom between the 
normal polypeptide backbone of SUMO precursor versus the unrestricted rotation in the 
long side chain of lysines create different potential steric-driven limitations on SENP 
activity (Komander et al., 2009; Shen et al., 2006).  In testing PPNDS in cell extracts, 
inhibition of deSUMOylation of natural substrates by full length SENP1 shows that 
PPNDS inhibition is not unique to our synthetic substrate or just the catalytic domain of 
SENP1.  PPNDS can inhibit SENP1 activity against a variety of natural cellular targets.  
 Both PPNDS (Class 2) and Suramin (Class 1) are published purinergic receptor 
antagonists, specifically the ionotropic P2X family of receptors (Coddou et al., 2011a, 
2011b).  A series of other known P2X receptor antagonists were tested against SENP1 and 
remarkably showed inhibition with some parallel rank order pharmacology in IC50 values.  
Despite no structural or functional similarity between SENPs and P2X receptors, the novel 
discovery of inhibition for SENP1 by P2X antagonists generates considerable anticipation 
as to other small molecules to test and suggests a potential mechanism of regulation of 
SENP1 that warrants future study.  
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Chapter 4  
 
Nucleotide-mediated inhibition of SENP1 
1. Introduction 
 
At the end of chapter three it was3 mentioned that both the class 1 and class 2 hits 
from HTS are known P2X1 receptor inhibitors.  P2X1 receptors are a member of a family 
of purinergic receptors, which bind extracellular nucleotides as a signaling molecule. 
Extracellular nucleotide release can be induced in a number of ways including via cellular 
shear stresses and damages, pathogen-associated molecular patterns (PAMPs), excitatory 
exocytosis from neurons as a neurotransmitter, and actively by ATP-binding cassette 
transporters (Gorini et al., 2013; Novak, 2003).  There are two types of purinergic (P2) 
receptors; there are the ionotropic, fast-acting P2X receptors that act as ligand gated ion 
channels, and there are the metabotropic P2Y receptors that function as G-protein coupled 
receptors (GPCRs).  While P2Y receptor activation can occur via ATP, ADP, UTP, UDP, 
or UDP-glucose nucleotides, P2X receptors are activated only by ATP, among naturally 
occurring nucleotides.   
                                                
‡ Carrie Johnson performed selective inhibition by ATPyS, as well as nucleotide structure 
activity relationships, and the kinetic characterization of ATP inhibition.  In collaboration 
with Dr. Jorge Iñiguez-Lluhí, Carrie M. Johnson performed MANT-ATP fluorimetry.  Dr. 
Marcelo Murai performed all NMR experiments, data analysis, and figure generation. 
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There are seven different subtypes of P2X receptors (P2X1-7) in eukaryotes.  Each 
monomer has two transmembrane domains with a large extracellular loop, but they 
assemble as homo- or heteromeric trimers. They are found throughout the body, including 
in smooth muscle, the heart, central and peripheral nerves, and immune cells and platelets. 
Upon receptor activation, channel opening allows for an influx of sodium and calcium ions 
for cell depolarization or cytosolic signaling.  The receptors vary in their rates of 
desensitization, ranging from milliseconds to seconds, and other than common ATP 
binding function, P2X receptors also differ markedly in their allosteric regulation by 
metals, small molecules, and protons (Coddou et al., 2011a; King et al., 1996; Lorca et al., 
2005; Roberts et al., 2006). With no typical structural ATP binding motifs or sequences, 
(e.g. Walker motif), found in P2X receptors, agonists and antagonists with specificity 
towards certain subtypes have been difficult to generate (Roberts et al., 2006; Walker et 
al., 1982). Based upon mutagenesis studies and recent crystal structures of zebrafish P2X4 
receptors in the open and closed states, ATP binding occurs at the interface between each 
monomer of the trimeric receptor (Evans, 2010; Hattori and Gouaux, 2012; Hausmann et 
al., 2015; Kawate et al., 2009).  ATP binding occurs in the bulky part of the extracellular 
domain in a pocket lined with numerous positively charged residues, propagating allosteric 
changes to the transmembrane helices to widen and open up the ion channel (Hattori and 
Gouaux, 2012).  For receptor activation, at least two of the three ATP binding sites must 
be occupied (Coddou et al., 2011b).  With this newer structural information, the field has 
been able to move beyond the existing fairly promiscuous chemical probes against P2X 
receptors and generate small molecule antagonists more selective to P2X receptor 
subtypes.  Efforts targeting specific P2X receptor subtypes have been directed towards 
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P2X4 and P2X7 receptors for their potential therapeutic roles in chronic and neuropathic 
pain, inflammation, and neurodegenerative and autoimmune diseases (Bartlett et al., 2014; 
Jacobson and Gao, 2016).  Just as it is essential to explore the binding mechanisms and 
breadth of ligands for modulating P2X receptor activity to generate potential therapeutics, 
it is essential to study potential inhibitors of SENP enzymes due to their roles in disease. 
In this work, the natural agonist for P2X receptors, ATP, is studied as a potential 
SENP1 inhibitor.  With our robust FRET assay, the mechanism of inhibition was 
determined in an unbiased fitting to reveal selectivity of inhibition for SENP1 over SENP2.  
Evidence for direct binding of ATP by SENP1 was obtained through multiple approaches.  
SENP1 residues responsible for selectivity were assessed and brief structure activity 
relationships were obtained regarding ATP analogs.  
 
2. Materials and Methods 
 
SENP1 and SENP2 construction, expression, and purification.  Plasmids for lac 
promoter driven expression of N-terminal His-tagged SENP1 (AA 418-C) and SENP2 (AA 
363-C) catalytic domains were constructed in the pHT2 backbone.  Rosetta 2 (DE3) E. coli 
cells were transformed with the plasmids and grown under carbenicillin selection. For 
expression,  cultures (1L per flask) were inoculated and grown at 37 °C. Upon reaching a 
density of OD600 1.1, cultures were shifted to 18 °C and isopropyl b-D-1-
thiogalactopyranoside was added to a final concentration of 0.2 mM.  Cultures were 
harvested after a further 20 hour incubation.  All subsequent purification steps were 
performed at 4 °C. Cells were harvested by centrifugation and suspended in Lysis Buffer 
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(10 mM Tris HCl pH 8.0, 500 mM NaCl, 5% glycerol, 2 mM imidazole, 1 mM b-
Mercaptoethanol, 0.5 mM PMSF, 0.5 µL benzonase).  Cells were disrupted by three passes 
through a French Press and a cleared lysate was obtained by centrifugation at 40,000 x g 
for 45 min at 4°C.  Protein was purified from the lysate using Ni-NTA affinity 
chromatography and stored in 300 mM NaCl, 50 mM Tris HCl pH 7.5, and 1 mM 
dithiothreitol. 
 
In Vitro FRET assay. Reactions were 100 µL final and performed in high or low salt 
buffer solution (20 mM TrisCl pH 8.0, 250 µM Na·EDTA, 20 mM NaCl or 100 mM NaCl, 
10 mM b-Mercaptoethanol, 0.1 mg mL-1 bovine serum albumin, 0.01% NP-40). Reactions 
were initiated by the addition of substrate and fluorescence was read every minute on a 
Spectramax M5 plate reader excitation at 405 nm and emission measured at 475 and 525 
nm. 
 
MANT-ATP Fluorimetry.  Methods and data fitting in possession of Dr. Jorge Iñiguez-
Lluhí. 
 
Cloning, expression and purification 
For NMR studies, the gene sequence of SENP1 (aa 419-644) containing the point mutation 
C603S was synthesized by GeneArt Gene Synthesis (Invitrogen) and subcloned into 
pET24a (Novagen) digested with EcoRI and BamHI restriction sites. All clones were 
verified by analytical digestion and automated sequencing.  The 15N-labeled SENP1 
protein was expressed by growing bacterial cells in isotopically enriched M9 minimal 
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media.  SENP1 was expressed in BL21-codon plus (DE3) and purified using affinity 
chromatography Ni-NTA (Qiagen) followed by SP Sepharose FF (GE Healthcare).  The 
following point mutations were generated using site-directed mutagenesis (R449E, 
W465A, E469K, T495A, T503A, Q507A, T451R, K455G, K515G, and the double mutants 
L530R,G531K and K455G,K515G) for nucleotide binding studies.  Expression and 
purification of mutants for enzymatic assays were carried out using one-step purification 
with nickel affinity beds. 
  
NMR spectroscopy 
For NMR experiments, the 15N-labeled SENP1 C603S sample was prepared at a final 
concentration of 80-100 µM in 20 mM sodium phosphate, pH 6.8, 5 mM DTT, 0.02% 
NaN3 and 10% D2O.  Chemical shift assignments of SENP1 C603S were obtained as 
previously described (BMRB entry19083).  NMR measurements were performed using a 
Bruker Advance III 600-MHz spectrometer equipped with 5-mm TCI cryogenic probe.  To 
determine binding affinity, 15N-labeled SENP1 C603S was titrated with MANT-ATP, and 
chemical shift perturbations were measured from heteronuclear single quantum coherence 
(HSQC) spectra.  
 
3. Results 
 
Inhibition by ATP 
 Upon observation that known P2X1 inhibitors also inhibited SENP1 with some 
parallel pharmacology, the natural P2X1 endogenous agonist, ATP, was tested for its 
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effects on SENP1.  Using Adenosine 5'-O-(3-thiotriphosphate) (ATPgS), a hydrolysis-
resistant form of ATP where the gamma or tertiary phosphate contains a thio-linkage, 
SENP1 was inhibited in a dose-responsive manner with an IC50 of 463 µM (Figure 4-1A).  
To assess for selectivity of ATP as an inhibitor, SENP2 was also tested.  Under the same 
low salt conditions (20 mM NaCl) that were used when testing SENP1, confounding salt 
effects from titration of ATPgS, a tetralithium salt, were observed so SENP2 inhibition had 
to be performed under its own optimal conditions (100 mM NaCl) for comparison.  SENP1 
Figure 4-1 Selective inhibition of SENP1 by ATPγS. 
Dose-response curves for SENP1 WT and SENP2 WT at 20 mM salt (low salt) and SENP2 
WT at high salt (100 mM).  B) IC50 values and inhibitory constants for inhibition by ATPγS 
of SENP1 and SENP2 at their ideal salt concentrations.  
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showed nearly ten-fold selectivity over SENP2 for ATP-mediated inhibition in the dose-
response FRET-based assay.  The estimated inhibitory constant using the Cheng-Prusoff 
equation reveals a nearly 20-fold ATP selectivity for SENP1 (Figure 4-1B and 4-5B). 
 Taking advantage of our previous detailed kinetic analysis on SENP1 and SENP2 
in chapter two, the ATP inhibitory constant and mechanism of inhibition for both enzymes 
were obtained.  With each enzyme tested under its respective optimal salt conditions, the 
affinity of SENP2 for SUMO1 compared to SENP1 is over 40-fold weaker (Figure 4-1B).  
This highlights the importance of how IC50 values are assay specific and are a reflection of 
a composite of kinetic constants that make it difficult to make strong comparisons.  
Therefore, while ATP is still a competitive yet weaker inhibitor of SENP2 than SENP1, it 
exhibits a greater degree of selectivity in the ATP binding constant than was anticipated 
based upon the IC50 values from the dose-response assay.   
 
Direct binding using MANT-ATP 
Though the FRET-based assays to measure SENP activity are quite powerful and 
high throughput in identifying and characterizing inhibitors, they are activity-based assays 
that offer indirect evidence of ATP inhibitor-SENP1 binding.  To gain orthogonal evidence 
of ATP-mediated inhibition, an ATP analog with a fluorophore conjugated to the 2’ or 3’ 
position of the ribose ring was employed.  This analog, 2’/3’-O-(N-Methyl-anthraniloyl)-
ATP, abbreviated MANT-ATP, has intrinsic fluorescence with optimal excitation near 350 
nm and emission at 448 nm.  This optimal MANT-ATP excitation overlaps with the 
emission of amino acids with intrinsic fluorescent properties, like tryptophan and tyrosine, 
when they are excited at 280 nm.  The large spectral overlap allows energy transfer to occur 
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between the protein and bound MANT nucleotides and resulting in a decrease in protein 
fluorescence at 350 nm and generation of a FRET signal at 448 nm (Figure 4-2A and B).  
With energy transfer as a function of distance between the fluorescent amino acids and the 
Figure 4-2 Direct ATP binding via MANT–ATP. 
A) Emission spectra of SENP1 alone, MANT-ATP alone, and the two together after excitation 
at 286 nM.  B) Cartoon representation of SENP1 protein to MANT-ATP FRET activity. C) 
Overlay of fluorescence emission curves starting with SENP1 protein alone and titration of 
MANT-ATP in to the mixture.  D) Representative plot of the change in fluorescence intensity 
at 448 nM with respect MANT-ATP concentration. E) Table of experimental dissociation 
constants for three nucleotide derivatives of MANT-ATP. 
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MANT that decays to the sixth power as distance increases, this experimental approach 
provides strong supporting evidence of direct ATP binding.  
Upon excitation at 286 nm, titration of MANT-conjugated ATP derivatives 
generated a decrease in signal at 350 nm and simultaneous increase in signal at 448 nm 
(Figure 4-2C).  In plotting the change in fluorescence intensity and quantitating the 
dissociation constant for the titrated MANT species, inner filter effects were accounted for 
to limit the pitfalls of numerous potential confounding factors (Niranjan et al., 2013).  
Primary inner-filter effects occur when there is non-homogenous excitation throughout the 
sample due to absorption of the excitation light causing each successive layer of solution 
to receive less and less light flux (Fonin et al., 2014; Kubista et al., 1994).  Secondary 
inner-filter effects occur when there is reabsorption of the fluorescence, like when unbound 
MANT derivatives absorb the protein fluorescence.  As seen in the emission spectra of 
SENP1 alone (blue) and MANT-ATP alone (black) after excitation at 286 nm, the protein 
contributes some fluorescent signal at 448 nm and the MANT derivative is capable of 
excitation and emission in the absence of its FRET partner (Figure 4-2A).  Because MANT-
ATP also partially absorbs the excitation light at 280 nm, it contributes to a strong primary 
inner-filter effect.  Titrations of protein alone and MANT-derivatives alone were used to 
offset the inner filter effect contributions in calculating dissociation constants.  An example 
of a data set used in determining the dissociation constant for MANT-ATP is shown in 
Figure 4-2D with a summary of three commercially available MANT-ATP derivatives 
shown in Figure 4-2E.  In addition to providing evidence supporting direct binding of ATP 
with SENP1, this small data set shows a preference by SENP1 for triphosphates and loss 
of the electron donating effects of a hydroxyl group bonded to the ribose sugar. 
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Nucleotide Structure Activity Relationships  
 With multiple approaches supporting inhibition of SENP1 by ATP, numerous 
nucleotide analogs were purchased to assess structure activity relationships (SAR) in 
SENP1 inhibition using the FRET-based SUMO assay.  A full table of the log IC50 values 
(pIC50) for each nucleotide analog is found in the appendix, but notable derivatives and 
their trends are shown in Figure 4-3.  The natural nucleotides and their deoxy- and 
dideoxyribose forms in Figure 4-3A, show a trend amongst all bases that the deoxyribose 
is more potent than ribose and the dideoxyribose form is the most potent.  Additionally, 
the purines, adenosine and guanine, are more potent than the pyrimidines.   
 The effects of other ribose modifications are shown in Figure 4-3B with the 
potencies of the ATP, dATP, and ddATP marked for reference.  In the top row of analogs, 
the 2’ hydroxyl group off the ribose was replaced with an electron withdrawing halogen or 
azido group. Despite the change from electron donating (hydroxyl) to withdrawing, the 
potency is largely unchanged from dATP.  Additionally, the size of modification in this 
position also seems to have little effect on potency, as atomic and ionic radii of iodine are 
approximately two times the size of those for fluorine.  Looking at the electron donating 
modifications in the bottom row, the primary amine analogs have reduced potency against 
SENP1 whereas the methoxy analogs show similar or increased potency compared to 
dATP.  Though both groups are of similar electron donating potential, they have opposite 
SAR regarding rank order effects on modification at the 2’ and 3’ positions. Together, these 
two donating groups generate inhibitors that are both more and less potent than the electron 
withdrawing analogs, thereby limiting a general conclusion on the roles of electronics on 
potency. 
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Figure 4-3 Nucleotide Structure Activity Relationships (SAR). 
A) Plot of the log of the IC50 values of each type of nucleotide base in their ribose, deoxyribose, 
and dideoxyribose forms as determined by a dose-response assay using the SFCypet-SUMO1-
SFYpet substrate. B) The logIC50 of ATP analogs containing different substituents off the 
ribose ring.  Analogs with electron withdrawing substituents are in the top row of data points 
and analogs with electron donating substituents are in the lower row.  The pIC50 values for 
ATP, dATP, and ddATP from (A) are noted in the x-axis with a vertical dashed line for 
reference. C) Effect of phosphate length in purine nucleotides on potency towards SENP1 
inhibition. Adenosine monophosphate was also tested and showed no inhibitory activity. 
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 In the last series of nucleotide SAR (Figure 4-3C), the effects of the length of the 
phosphate are explored.  For both ATP and GTP, the hydrolysis-resistant gamma-thio 
analogs showed enhanced potency.  The diphosphate showed a further reduction in potency 
and the monophosphate (data not shown) had no inhibitory effect on SENP1.  Given the 
trend that loss of phosphate reduces inhibitory activity, it is difficult to discern if the 
intrinsic chemistry of sulfur in the gamma-thio analogs is responsible for the enhanced 
potency or if it is a product of the reduced hydrolysis of the gamma phosphate and a 
preservation of potency. The data from the SAR work on ATP analogs in these dose-
response FRET-based experiments is in agreement with the brief SAR from the MANT-
ATP fluorimetry work, where the dATP derivative had a stronger affinity than ATP and 
the diphosphate was weaker than both the triphosphate ATPs.   
 
HSQC NMR analysis of nucleotide binding to SENP1  
 With evidence for direct ATP binding, 2D HSQC NMR was employed by a 
member of the lab (Dr. Marcelo Murai) to discover and evaluate the SENP1 residues likely 
involved in ATP binding.  The same SENP1 construct was generated that was used in the 
previously assigned HSQC NMR of SENP1 and grown in 15N labeled media (Madu et al., 
2013).   
 Though the amide backbone of all residues are not assigned, among those that were 
identified, chemical shift perturbations were monitored throughout the titration of MANT-
ATP into SENP (Figure 4-4A and B).  The residues showing shifts in their NMR signature 
were mapped to the crystal structure of SENP1 according to the magnitude of their shift 
(Figure 4-4C).  The residues in red had the largest perturbations in their amide backbone, 
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followed by orange and yellow, and show that many of the residues most perturbed in 
relation to MANT-ATP binding are near the SUMO binding site where the SUMO1 the b 
Figure 4-4 SENP1 HSQC NMR of MANT–ATP titration. 
A) A portion of the HSQC NMR spectra for MANT-ATP titration into SENP1 WT, 
highlighting the chemical shift perturbations for the backbone amide of residue Glu 469.  B) 
Plot of most perturbed residues in SENP1 WT as a function of MANT-ATP concentration.  C)  
Heat map of SENP1 crystal structure depicting location and general scaling of chemical shift 
perturbations from MANT-ATP titration (in order from most to least perturbed: red, orange, 
yellow, green; blue means unperturbed and gray is for unassigned residues. D) Figure of panel 
C in complex with SUMO1 to give reference to the location of the most perturbed residues.  
E) Residues in green are those that are directly involved with SUMO binding.  HSQC NMR 
experiments and analysis performed by Dr. Marcelo Murai. 
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grasp domain  interacts with SENP1 (Figure 4-4D).  Among the residues assigned and 
shown, the strongest shifts in their backbone N-H bond are Thr495, Glu469, and Arg449, 
with Glu469 and Arg449 as amino acids known for making direct contacts with SUMO 
(Figure 4-4E). This overlapping location of SUMO and ATP binding supports earlier 
observations that ATP is a competitive inhibitor of SENP1.   
 
Probing of SENP1 residues to understand ATP selectivity 
 Following analysis of the HSQC NMR spectra in the presence of ATP, a subset of 
the residues showing the strongest chemical shift perturbations were selected as targets for 
mutagenesis. In testing the mutants for general SUMO protease activity, SENP1 E469K 
was subjected to further testing to probe the residues responsible for the selectivity seen 
between SENP1 and SENP2 in inhibition by ATP.  Additionally, the SENP1 mutants 
generated for previous studies in chapters two and three, K455G, K515G, and the double 
lysine mutant, K455,515G, were also tested for inhibition by ATP.   
 Inhibition by ATP was observed for the lysine mutants, with potencies falling in 
between the wild types for SENP1 and SENP2 (Figure 4-5A).  Using the average IC50 
values for ATP inhibition and the kinetic constants for each enzyme determined in chapter 
two, an estimated inhibitory constant was calculated using the Cheng-Prusoff equation 
described in Figure 3-7 of chapter three.  With the estimated Ki values as a guide, detailed 
kinetic characterization of the WT and mutant enzymes was undertaken to generate an 
experimental Ki (Figure 4-5B).  With the exception of SENP2 WT, the Ki values from the 
Cheng-Prusoff were reasonable estimations for the experimentally determined values.  
SENP1 WT remains the enzyme form for which ATP is most potent in inhibition, with the 
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K515G and K455,515G showing the largest deviations from SENP1 WT.  For K455G, the 
lysine at this position enhances substrate binding but has no effect on the ATP inhibitory 
constant, suggesting that there are non-overlapping residues important for ATP versus 
Figure 4-5 ATP binding characterization. 
A) Dose-response plot of ATPγS inhibition of different SENP1 mutants and SENP1 and 
SENP2 WT.  B) Table of kinetic constants obtained using previous detailed kinetic analysis.  
Using the IC50 values determined via the ratiometric FRET assay, inhibitor constants were 
estimated using the Cheng-Prusoff (C-P) equation.  Experimental inhibitory constants were 
obtained directly through the channel2 mediated analysis of the FRET-based substrate assay.  
Graphical presentation of experimental Ki values for each of the SENP1 mutants and SENP2 
WT. ND = no data. 
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SUMO binding.  In contrast, K515G shows that this residue is important for both ATP and 
SUMO substrate binding, while the double mutant data shows that the addition of the 
K455G mutation is not sufficient to overcome the loss of binding affinity created by 
K515G.  Despite strong chemical shift perturbations, change in charge at 469 from Glu to 
Lys has little to no effect on substrate binding and ATP-mediated inhibition.  
4. Discussion 
 
 This work exhibits a unique transition of leveraging the parallels of small molecule 
inhibitors of an unrelated protein to the discovery of novel inhibitors for SENP1.  In 
probing ATP-mediated inhibition through orthogonal approaches, regions of SENP1 and 
specific residues within those regions were identified for their involvement in ATP binding.  
Additionally, preliminary structure activity relationships offer insight into potential further 
rational drug design for development of selective, small molecule probes to then selectively 
study SENPs in more biological settings than tests with purified protein. 
 Unlike other identified SENP inhibitors, the structural evidence for ATP-mediated 
inhibition suggests that it binds away from the catalytic site and instead in the SENP1 
pocket responsible for binding to the globular portion of SUMO, the b grasp domain.  As 
seen in the conserved binding site for ATP in P2X receptors, one side of this binding pocket 
on the surface of SENP1 contains a patch of positively charged residues that could be 
responsible to binding to the ATP triphosphate moiety.  Some of these positively charged 
residues are the same residues or near the same residues most perturbed in the HSQC NMR 
experiments with MANT-ATP.  For labs who employed in silico screening or structure-
based drug design to initiate SENP inhibition and to further advance potency using docking 
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studies, inhibition was targeted near the catalytic site (Chen et al., 2012; Madu et al., 2013).  
Specificity for SENP1 over other cysteine proteases and within the SENP family was 
attempted by incorporating the steric constraints of the tryptophan tunnel and designing 
aromatic portions to engage in pi-bond stacking with His529 and Phe496.  While a 
desirable strategy for selectivity, it could make potent inhibition difficult.  Most of the 
binding affinity by SENPs is driven by interaction with SUMO’s b-grasp domain and the 
SUMO C-terminal tail seems to sway in both SUMO-bound and unbound states (Chen et 
al., 2014).  Whether substrate bound or not, conformational dynamics show that the 
catalytic tunnel experiences extensive dynamics, opening and closing over a range of 
timescales.  The tryptophan residue that serves as the lid for the catalytic tunnel generation, 
Trp465, is especially susceptible to these conformational changes.  When SUMO and 
SENP1 bind through SUMO’s b-grasp domain, it induces an allosteric effect that 
propagates from this b-grasp binding surface to the catalytic tunnel to align the catalytic 
residues for optimal proteolysis. Therefore, if a potential inhibitor binds to the minimal 
contacts near the catalytic tunnel, binding of the globular portion of SUMO and the robust 
allostery it induces could kick off the inhibitor that bound to the enzyme conformation 
where SUMO is not also bound.  Alternatively, using strategies to target a small molecule 
inhibitor near the SENP1 catalytic tunnel in the SUMO-unbound state, it could operate as 
a negative allosteric modulator, locking the residues in a confirmation suboptimal for 
catalysis.    
 While much is known about the enzymology and SUMO isoform selectivity among 
the SENP family enzymes, very little is known about their regulation. Considering their 
roles in precursor processing to allow SUMOylation to occur up front and then in reversing 
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the modification, it is essential to gain a better understanding of how SENP activity is 
regulated.  There is some understanding of SENP regulation as a product of their variable 
N-terminal domains (NTDs) and role in dictating localization.  In addition, the NTDs of 
many of the SENPs contain SUMO-interacting motifs (SIMs) described in chapter one that 
may play a role in regulating their activity, but preliminary work suggests that they are not 
relevant for enzyme activity in vitro (Kerscher, 2007; Mendes et al., 2016).  As an isolated 
observation, SENP1 has been found to be SUMOylated itself by SUMO2/3 but the 
ramifications of that modification on SENP1 function are unknown (Sharma et al., 2013).  
Just as there are a few proteins involved in the SUMOylation compared to the 
ubiquitination system, there is also a similar discrepancy in the number of proteins involved 
in their deconjugation systems.  There are nearly 100 deubiquitinases but only six 
deSUMOylases, yet both PTMs are exquisitely involved in many essential cell functions 
and cause disease or death when they go awry.  Clearly, regulation of the SUMO system 
in some manner is necessary for homeostasis.   
With ATP as an abundant biological molecule that is at the crux of cell metabolism 
and function, and SUMO’s role in processes regarding mitosis, DNA repair, and cell stress, 
it is possible that SENP activity could be linked to energy regulation in cells.  Though the 
inhibitory and binding constants for ATP are not potent relative to most relevant small 
molecule therapeutics, the values are in this case in the context of intracellular ATP 
concentrations, which range approximately from low micromolar to 5 mM (Ando et al., 
2012; Imamura et al., 2009; Novak, 2003).  Throughout a cell’s life cycle, ATP levels are 
dynamic and can oscillate depending on the cell stage as their demands and homeostatic 
challenges change (Tyson, 2002; da Veiga Moreira et al., 2015). Therefore, with similar 
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parallels in SUMO’s role in responding to these various homeostatic challenges and 
progressions through the cell cycle, it is possible that energy levels as determined by ATP 
concentrations could regulate SENP activity.  The logical next step might be to test the 
effects of manipulating ATP levels on protein SUMOylation and function of specific 
SUMOylation-regulated transcription factors. The challenge in this approach is that in 
assessing SENP function, confounding factors would make analysis difficult because ATP 
is necessary for initial SUMOylation.  Additionally, with SENPs playing roles in both the 
maturation and reversal of SUMO modification, teasing out the role of ATP in the 
individual components of SUMO processing, conjugation, and deconjugation would be 
particularly challenging.  Nonetheless, the potential for discovering an understanding of 
regulation of the SENP family of enzymes is intriguing. 
 In addition to the potential implications for a SENP regulatory mechanism, our 
initial foray into nucleotide structure-activity relationships can be leveraged to generate 
increasingly selective, potent, and ultimately cell permeable inhibitors.  This will not be 
simple, as our initial attempts at generating these types of compounds with the help of Jeff 
Zwicker in Dr. Scott Larsen’s lab were unsuccessful.  Because of the commonality of ATP 
binding in the human proteome and the potential for cross reactivity, it is imperative to 
develop selective inhibitors.  The purinergic receptor field has begun to be able to generate 
ligands selective not just for purinergic receptors in general, but for specific subtypes 
within the ionotropic family of purinergic receptors.  These new generation ligands were 
tested and, with their enhanced selectivity, do not inhibit SENP1 (data not shown).  Due to 
conflicting data across species types and receptor truncations, the purinergic field has also 
recognized the importance of using the human version of the protein, and the full-length 
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version as well.  With the NTD of SENPs containing SIMs and serving functions in 
localization, it is important to try to use full-length enzyme when possible.  Similarly, 
Mendes et al. found new results when characterizing SENPs upon using full length enzyme 
as opposed to the catalytic domain that was used in previous studies (Mendes et al., 2016).  
As the SUMO field advances, transitioning into using full-length SENP enzyme will likely 
become necessary to achieve a detailed understanding despite the difficulties in its 
synthesis and purification.   
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Chapter 5  
 
Conclusions and future directions 
1. Overview 
 
 Since the discovery of SUMO as a PTM in 1996, many have sought to understand 
its targets, its roles in modulating protein function, and the implications of its effects in 
disease contexts.  Though many SUMO targets have been found in the nucleus, 
SUMOylated proteins have also been found in the cytoplasm and in transmembrane 
proteins of the endoplasmic reticulum, plasma membrane, Golgi apparatus, and outer 
mitochondrial membrane (Flotho and Melchior, 2013).  As a reversible modification with 
highly dynamic and rapid cycles of SUMOylation and deSUMOylation, SUMO can act as 
a molecular switch in modulating protein function.  With roles in numerous cancers, 
Huntington’s Disease, Alzheimer’s Disease, amyotrophic lateral sclerosis, Parkinson’s 
Disease, dilated cardiomyopathy, and other diseases, numerous studies of the SUMO 
system have been performed (Sarge and Park-Sarge, 2011).  In the context of prostate 
cancer, preservation of SUMOylation of the androgen receptor (AR) helps limit 
transcription of AR-regulated genes and therefore the proliferation of the cancer.  As 
described in chapter 1, antagonizing this suppression of transcription is the SUMO protease 
SENP1. SENP1 is overexpressed in advanced prostate cancer and can initiate progression 
of healthy prostatic tissue into the cancer precursor, prostatic intraepithelial neoplasia 
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(Bawa-Khalfe et al., 2010).  Therefore, we attempted to identify novel small molecule 
inhibitors of SENP1. 
 
2. Summary and impact of results 
 
 In this work, a FRET-based approach was employed to initialize the search for 
SENP1 inhibitors with potential therapeutic implications.  A ratiometric analysis of the 
substrate’s fluorescent emissions was ideal for small-volume high throughput screening 
because it can account for small changes in substrate concentration from well to well.  After 
screening over 500,000 compounds, an iterative process of utilizing different set-ups of the 
ratiometric FRET assay in dose-response and time course formats generated the desired 
funnel-like effect of the narrowing of candidate compounds in drug discovery.   
While assessing the selectivity of some of these inhibitors for SENP1 versus 
SENP2, a differential salt sensitivity of the enzymes was observed.  Though it may seem 
like a minor issue, this observation is surprisingly novel to the SUMO protease field.  Due 
to the array of diseases where SENP1 has implications, there have been many efforts to 
develop SENP1 inhibitors.  Yet when these groups are testing inhibition against SENP2 
and attempting to further drive the potency and selectivity towards SENP1, potential 
structure activity relationships may be misleading because of the suboptimal testing 
conditions. Through the careful monitoring and standardization of channel 2 signal at 525 
nm, further analysis of these salt effects offered a more detailed characterization of the 
consequences ionic strength on SENP1 vs SENP2 proteolytic activity.  This detailed 
characterization for teasing out the individual kinetic constants facilitated probing specific 
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residues for their roles in substrate binding, product binding, and catalysis.  Lastly, this 
approach to analysis also permits unbiased determination of the mechanism of inhibition 
of identified small molecule inhibitors, which can aid in the development of better 
inhibitors.  The results presented here demonstrate the importance of characterizing each 
enzyme separately and the robust utility of the generated FRET substrate in the discovery 
and further characterization of SENP enzyme inhibitors regarding their mechanism of 
inhibition, structure activity relationships, inhibitory constants, and residues important for 
inhibitor binding.  
Among the most unique findings of this work and with potentially the greatest 
impact is the parallel pharmacology of small molecule inhibitors between SENP1 and 
ionotropic purinergic receptors.   Observation of SENP1 inhibition by these small molecule 
antagonists and by ATP was certainly unexpected given no structural similarities to the 
two proteins and the absence of any canonical ATP binding motifs.  ATP was found to be 
a competitive inhibitor with Lys 515 in SENP1 showing evidence that it is involved in ATP 
binding.  Notably, this residue is in the same binding pocket of SENP1 where SUMO binds, 
and it is where a negatively charged surface patch of SUMO1 interacts with a positively 
charged patch of SENP1.  As a competitive inhibitor with three negatively charged 
phosphate groups, the partial dependence on a SENP1 lysine residue, among others, helps 
in creating a more cohesive understanding.  The HSQC NMR and MANT-ATP assays 
assessed direct binding instead of SENP activity, generating further supporting evidence 
for ATP-SENP1 interactions.  In agreement with the activity-based results, some of the 
backbone residues sensitive to ATP in HSQC NMR are near Lys 515.  If the R-group amine 
in the lysine were assigned it would be advantageous to monitor potential chemical shift 
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perturbations at this extended R group than just the effects on the backbone nitrogen-proton 
2D signal.  Though the initial structure activity relationships for nucleotides are brief due 
to our limited supply, they provide a potential starting point for guiding the further 
development of more potent and biologically stable SENP1 inhibitors.  
 
3. Regulation of the SUMO and AR systems 
 
 There are a multitude of reports on the functional effects of AR SUMOylation and 
the extensive biochemical, cellular, and clinical validation of SENP1 as a protein 
potentiating AR signaling and tumor growth.  Yet despite the plethora of SUMO literature 
in the past two decades, there remains very little understanding as to the exact mechanism 
of how SUMOylation represses AR transcription.  AR is predominantly deSUMOylated in 
the cytosol and becomes SUMOylated upon ligand binding-induced activation and 
translocation to the nucleus (Kaikkonen et al., 2008). There is evidence for SUMO-induced 
chromatin level effects, including the recruitment of histone deacetylases (co-repressors) 
to condense chromatin and prevent DNA-binding access by the general transcriptional 
assembly (Girdwood et al., 2003; Yang and Sharrocks, 2004).  Additionally, there is 
evidence for both a SUMO-mediated enhancement and reduction in AR occupancy at DNA 
androgen response elements, possibly in a gene selective manner (Rytinki et al., 2012). 
Pivoting within the DNA occupancy idea, hypotheses related to receptor clearance from 
the DNA response element and cycling of rounds of receptor have been argued both for 
and against suppressing transcriptional activity, especially in the context of competition for 
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modification between SUMO and ubiquitin-induced degradation  (Chymkowitch et al., 
2011; Kodadek et al., 2006).   
Beyond effects on AR, regulation of SUMOylation and deSUMOylation is also 
poorly understood.  Under resting conditions, most SUMO1 is conjugated to a substrate 
and there is large pool of free SUMO2/3.  Cell stress has reliably been shown to increase 
SUMO2/3 modification across the cellular proteome and there is supporting evidence for 
group-based SUMOylation where related target proteins are already in proximity to each 
other (Hendriks and Vertegaal, 2016; Saitoh and Hinchey, 2000).  For the SENPs, 
comprehension of their regulation is limited to the localization-directing effects of their 
differing N-terminal domains.  Importantly, regulation of SENP enzymes is especially 
integral for exquisite and timely implementation of SUMO functions due to its role in both 
precursor processing (SENP1 and SENP2) and deSUMOylation (true for all six SENPs). 
The results presented in chapters 2 and 4 point to two potential factors that could play a 
role in SENP1 and SENP2 regulation.   
First, in chapter 2 a differential salt sensitivity between SENP1 and SENP2 was 
observed with respect to their activity, kinetic constants, and SUMO processing isoform 
preference.  While the consequences of the differential sensitivity were discussed in the 
context of testing and developing selective small molecule inhibitors, there are also 
potential implications for regulation. In mammalian cells, the salt concentration in the 
nucleus is around twice that in the cytosol (~150 mM vs ~300 mM).  SENP1 and SENP2 
have been observed in both the nucleus and cytoplasm (Moore and Morrill, 1976; Terry et 
al., 2011).  Studies across the SUMO field have revealed that dynamic regulation of 
SUMOylation and its functions is essential for development and numerous other signaling 
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pathways.  While the salt-based data presented in this thesis were based on the catalytic 
domain of the enzymes and not the full-length enzyme, the contributions of electrostatics 
to SENP affinities for SUMO substrate and to peptide hydrolysis may help tune the activity 
of these proteases as they shuttle between different cellular locales. 
Regarding chapter 4, nucleotides and nucleotide analogs were found to inhibit 
SENP1 and to a lesser extent, SENP2.  With EDTA in the reaction buffer and no 
magnesium added, another unique characteristic of this ATP effect is that their inhibition 
is not magnesium-dependent unlike other enzymes that use ATP.  As the molecule that 
functions as the primary energy currency in a cell, ATP is tied to the essential function of 
healthy cell growth and homeostasis but also to cancer cell growth.  In highly proliferative 
cancers, the demands for ATP are substantially higher than those of healthy cells.  The 
cancer cells utilize ATP at a high rate to maintain their nearly unabated pace of growth and 
metabolism.  Therefore, in prostate cancer, the proliferative drive of the disease may lead 
to high turnover in ATP and an overall reduced cellular [ATP] as the cells strive to keep 
up with energy demands.  In this situation, should SENP1 activity be regulated by ATP 
inhibition near physiological concentrations, reduced ATP levels in cancer cells could 
further augment the role of SENP1 in prostate cancer progression. 
 
4. Exploration of future prostate cancer therapeutics 
 
 As described in chapter 1, beyond surgery, the three primary chemotherapeutic 
means to prostate cancer therapy all target the ligand-binding domain of AR either directly 
or indirectly.  Chemical castration, AR antagonism, and direct inhibition of androgen 
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synthesizing enzymes all cause initial shrinkage in the size of both the healthy and 
cancerous prostatic tissue.  When patients invariably fail these therapies, there are a few 
cytotoxic agents that can be employed to extend survival by a few months.  In other areas 
of cancer treatment such as melanoma and non-small cell lung cancer, immunotherapy has 
recently generated considerable momentum.  In prostate cancer, new generation 
immunotherapy has been around since the FDA approved Sipuleucel-T in 2010.  In this 
treatment, dendritic cells are harvested from the patient and cultured in the presence of 
antigens from the protein prostatic acid phosphatase (PAP) and an immune-stimulant for 
immune cell maturation.  In programming these immune cells to target PAP via co-culture, 
an amplified culture of these programmed cells is re-injected into the patient in hopes the 
immune cells will specifically recognize and ultimately kill the cancer cells.  Like the 
cytotoxic agents, this immunotherapy has been shown to increase survival by around four 
months (Small et al., 2006). 
 Considering the state of the disease and the lack of therapeutics that are effective 
over periods of time longer than a few months, there is continued motivation to develop 
new therapies.  As noted, immunotherapy is a modality that continues to develop and is 
offering exciting results in some other cancers despite the limited duration of efficacy thus 
far in prostate cancer.  Though there is worthy excitement over immunotherapy potentials 
across cancer types, within advanced prostate cancer, the disease is still largely dependent 
on AR.  Some efforts to curb this disease or generate cures are looking at alternative 
mechanisms to modulate AR-dependent transcription other than the traditional approaches 
related to the ligand binding domain.  Looking at other AR domains, there have been some 
reports of small molecules to target the DNA binding domain of AR (Dalal et al., 2014; Li 
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et al., 2014; Lim et al., 2014).  Others have targeted the N-terminal domain (NTD) of AR 
and its activation function (AF)-1 region to attenuate transactivation of AR and AR-
dependent transcriptional output (Andersen et al., 2010).  Improvements in drug delivery, 
selectivity, and durability for administration of siRNA allow for their future development 
as potential therapies targeting AR or other proteins implicated in advanced prostate cancer 
growth such as the ERG family of transcription factors (Feng et al., 2014; Tomlins et al., 
2008). In a unique approach developed by Dr. Craig Crews, the selective degradation of 
AR is employed as an alternative approach.  In these proteolysis-targeting chimeras 
(PROTACs), a heterobifunctional ligand, is used. These ligands have a target protein 
binding molecule on one end, dihydrotestosterone, and a protein degradation machinery 
recruiting unit, a ubiquitin E3 ligase, on the other end with a linker in between (Ottis and 
Crews, 2017).   
 While this sampling of strategies and others not mentioned to treat advanced 
prostate cancer have varying degrees of utility and prospective ability to become a 
therapeutic, targeting SENP1 offers unique advantages within the disease context.  With 
SUMOylation occurring in the NTD of AR, a SENP1 inhibitor could synergize with 
existing therapies that target the LBD.  In addition to the roles of SENP1 in potentiating 
AR activity and completing a positive feedback loop, other advantageous reasons for 
inhibiting SENP1 relate to its roles in radiosensitization, senescence, and metastasis.  In a 
lung cancer model, inhibition of SENP1 induced radiosensitization, suggesting that it could 
potentially decrease the amount of radiation needed to treat cancerous tissue (Wang et al., 
2013).  Both inhibition of SENP1 and hyperSUMOylation each induce senescence. 
(Kaikkonen et al., 2008; Li et al., 2006).  Lastly, SENP1 promotes epithelial to 
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mesenchymal transition and silencing of SENP1 induces apoptosis and slows proliferation 
and cell migration.  These are all important steps in metastasis, which is responsible for 
90% of cancer deaths (Hanahan and Weinberg, 2011).  Therefore, with SENP1 inhibition 
offering the many advantageous outcomes described, strategies to inhibit it remain 
attractive.  
 
5. Future directions 
 
Moving forward, the importance of the full-length enzyme in assessing regulatory 
mechanisms of SENP activity must be recognized.  Separate from the catalytic domain, the 
NTD is responsible for the localization of SENPs and shows less similarity between SENP 
enzymes.  Quantitative purification of full-length enzyme that contains this NTD remains 
difficult and lack of crystal structures of the non-catalytic domain regions makes it difficult 
to hypothesize what changes they might initiate in SENP regulation or selective inhibition. 
The nucleotide effects on SENP1 activity are particularly intriguing.  Back in 1956, 
Dr. Otto Warburg observed that cancer cells have an altered metabolism that allows them 
to survive stressful conditions while maintaining necessary proliferation for cancer 
progression and metastasis (Warburg, 1956).  In this altered metabolic state, the cancer 
cells increase their dependence on glycolysis over oxidative phosphorylation to meet their 
energy demands and lactic acid production rises.  To accommodate these demands, these 
cells also increase their rate of intracellular glucose importation, a characteristic utilized 
for positron emission tomography (PET) imaging with fluorodeoxyglucose in cancer 
patients.  With respect to this Warburg effect found in many cancer cells, changes in 
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cellular metabolism due to reduced utilization of oxidative phosphorylation and increased 
reliance on glycolysis may provide key support in regulating SENP1 activity.  With a 
potential for quick turnover between ATP production and rapid utilization in cancer cells, 
as ATP levels drop in prostate cancer cells, SENP1 activity may become enhanced to allow 
for more rapid proliferation.  As described above, inhibiting SENP1 would then not only 
repress AR transcriptional activity, but it could also lead to slowing cancer progression, 
radiosensitization, senescence, and lower metastatic potential. 
The challenge in elucidating a potential role for ATP-mediated regulation of 
SENP1 lies within the entire SUMOylation pathway.  The first step in preparation of 
conjugating mature SUMO to a substrate requires ATP.  Therefore, if ATP levels were 
manipulated in an attempt to assess effects on SENP1 activity in the cell, the SUMOylation 
process itself would be impaired and confound the results.  Therefore, the best way to get 
around this might be to develop a more selective and biologically stable ATP-mimetic to 
study SENP1 activity in a spatial and temporal manner. 
An additional interesting future research aim could involve comparing SENP1 
expression levels and ATP levels.  Analysis of three of the most utilized prostate cancer 
cell lines has previously reported that under normoxic conditions, LNCaP cells rely on 
respiration over glycolysis in contrast to PC3 and DU145 cells (Higgins et al., 2009).  This 
behavior for mechanism of ATP production parallels the concentrations of ATP within 
these cells.  Glycolysis is much less efficient than oxidative phosphorylation, and as 
anticipated, the PC3 and DU145 cells have much lower ATP levels than LNCaP cells.  
Within the context of these cells, it would be worth seeing if SENP1 expression levels have 
any relation to cellular ATP levels in the individual cell lines.  In regards to the current 
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model, lower ATP levels could lead to higher SENP1 levels due to the loss of SUMO-
based restraint on AR activity and the fact that SENP1 is a direct AR gene product.   
Additionally, transfection with labeled SUMO or blotting for endogenous SUMO would 
also be worth pursuing to see if levels of SUMO conjugated substrates differ with respect 
to ATP levels. 
Ultimately, SENP1 remains an attractive therapeutic target but a difficult chemical 
one.  With over two decades of a head-start, the ubiquitin field has also struggled to develop 
selective small molecule inhibitors (Huang and Dixit, 2016).  Even beyond potential 
therapeutic implications, the integral role of SUMO in numerous cell functions necessitates 
the development of better chemical tools to study the SUMO system in more dynamic, 
biologically relevant settings.  The findings and assay development presented in this thesis 
serve as valuable tools in advancing this process.  
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Appendix 
 
Table A1.1. Dose-response experiment results for nucleotide analogs. Hill 
coefficients from IC50 analysis determination also presented. 
 
		
Name	 Log	IC50	(M)	 Hill	coefficient	
1	 ATP	 -3.15	 -0.93	
2	 2',3'-ddATP	 -3.93	 -0.98	
3	 (L)-2'-dATP	 -3.68	 -0.83	
4	 Ara-ATP	 -3.70	 -0.91	
5	 3'-dATP	 -3.69	 -0.91	
6	 3'-O-Methyl-ATP	 -4.16	 -0.96	
7	 2'-O-Methyl-ATP	 -3.74	 -0.92	
8	 2'-dATP	 -3.69	 -0.95	
10	 2'-amino-2'-dATP	 -3.52	 -0.92	
11	 2'-azido-dATP	 -3.80	 -0.95	
12	 2'-fluoro-dATP	 -3.88	 -0.93	
13	 3'-amino-ddATP	 -3.12	 -1.07	
14	 3'-azido-ddATP	 -3.78	 -0.92	
15	 2'-Bromo-dATP	 -3.90	 -0.92	
16	 2'-Iodo-dATP	 -3.76	 -0.85	
18	 8-chloro-2'-dATP	 -2.47	 -1.05	
19	 8-oxo-2'-dATP	 -4.01	 -0.65	
20	 N1-methyl-ATP	 -2.85	 -1.09	
21	 N6-methyl-2-amino-ATP	 -3.61	 -0.99	
22	 N6-methyl-ATP	 -3.25	 -0.96	
23	 2-amino-ATP	 -3.56	 -1.01	
24	 7-deaza-ATP	 -3.38	 -0.93	
25	 8-aza-ATP	 -3.52	 -0.95	
26	 8-azido-ATP	 -3.76	 -1.01	
27	 2-aminopurine-TP	 -3.51	 -0.95	
28	 2-FluoroATP	 -3.33	 -0.91	
29	 8-Bromo-ATP	 -4.33	 -0.91	
30	 8-Iodo-ATP	 -3.73	 -1.12	
31	 7-deaza-7-iodo-dATP	 -3.99	 -0.99	
32	 2-Methyl-thio	ATP	 -3.56	 -0.88	
33	 6-thio-2'-dGTP	 -4.34	 -0.93	
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34	 8-oxo-GTP	 -3.15	 -0.90	
35	 7-deaza-GTP	 -3.36	 -0.95	
36	 N2-methyl-2'-dGTP	 -3.64	 -0.98	
37	 N1-methyl-GTP	 -3.83	 -0.93	
38	 O6-methyl-GTP	 -3.86	 -0.93	
39	 GTP	 -3.09	 -0.91	
40	 dGTP	 -3.72	 -0.94	
42	 Ganciclovir-TP	 -3.67	 -1.06	
43	 2',3'-ddITP	 -3.93	 -0.98	
44	 ITP	 -3.50	 -0.96	
45	 2-amino-6-Chloro-Purine-TP	 -3.92	 -0.88	
46	 xanthosine-TP	 -4.08	 -0.86	
47	 6-chloro-purine-TP	 -3.46	 -0.89	
48	 thieno-GTP	 -3.90	 -0.97	
49	 α1-Thio-ATP	 -3.91	 -1.00	
50	 α1-Borano-2'-dATP	 -3.73	 -1.01	
51	 2-iodo-ATPgammaS	 -4.49	 -0.87	
52	 8-iodo-AppNHp	ATP	 -3.28	 -1.20	
53	 2'-iodo-2'-deoxyadensine-5'-[(β,γ)-imido]triphosphate	 -3.25	 -0.96	
54	 GTP	 -3.20	 -1.01	
55	 GTPyS	 -3.71	 -0.94	
56	 ATP	 -3.19	 -0.90	
58	 5-nitro-1-indolyl-2'-dATP	 -4.29	 -1.02	
59	 2'-dZebularine-TP	 -4.23	 -0.90	
60	 Puromycin-triphosphate	 -3.65	 -1.08	
 
